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SUMMARY 
Study premises: Diabetic retinopathy (DR), one of the leading causes of 
blindness in developed countries, represents the most common microvascular 
complication of diabetes mellitus. Recent studies have shown that the alteration 
of glial cells and the resulting loss of neuronal cells occur before the vascular 
lesions become clinically detectable.  
Study purpose: The purpose of the study is to find the early biomarkers of glial 
activation in the aqueous humour of diabetic subjects, both in presence and the 
absence of clinically detectable DR signs. 
Materials and methods: During cataract surgery, samples of the aqueous 
humour have been collected in 34 patients, divided as follows: 12 healthy 
subjects, 11 diabetic patients without diabetic retinopathy and 11 patients with 
the non proliferative diabetic retinopathy (5 without macular edema-ME and 6 
with ME). Before intervention, every patient has undergone a complete 
ophthalmic examination and the spectral domain optical coherence tomography 
(SD-OCT) (Spectralis HRA+OCT, Heildeberg Engineering). In 34 samples, the 
quantification of total proteins has been carried out using the Bradford method, of 
GFAP, AQP1 and AQP4 using the ELISA test, and of 40 inflammatory cytokines 
using the protein array. In addition, the segmentation of the retinal layers has 
been carried out using the SD-OCT scans.  
Results: Mean concentration of GFAP, AQP1 e AQP4 was significantly 
increased in diabetics versus controls (p<0.05). GFAP showed an approximate 
0.8 fold increase, AQP1 1.1 fold increase, whereas AQP4 about 24 folds increase 
in diabetic patients versus controls. When we separately evaluated DR-no ME 
eyes vs DR-ME eyes, there was a significant decrease in GFAP, AQP1 e AQPR 
in DR-ME eyes versus DR-no ME eyes,  (Tukey Kramer post hoc p<0.05). 
Following cytokines were increased in diabetic patients (with or without DR) 
compared to healthy subjects: GFAP, AQP1, AQP4, IFNy, IL-1a, IL-1b, IL-3, IL-4, 
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IL-10, IL-11, IL-17, TNF- α, TNF-ß, MCP1, MCP2, Eotaxin, Eotaxin 2, RANTES, 
sTNFRII, GM-CSF, IP-10, MIP1a, MIP1b. The mean macular thickness of RNFL 
was significantly higher in diabetic patients with DR and ME compared to 
diabetics without ME (both with and without DR) and healthy subjects, and the 
same significance was observed in the inner and the external rings and in the 
superior, inferior and temporal sectors. The mean thickness of RNFL was 
significantly reduced in diabetics with DR and without ME compared to healthy 
subjects. 
Conclusions: In the aqueous humour of diabetic subjects, 23 different protein 
biomarkers of glial activation have been found already in the subclinical stage of 
DR. They can be used in future as risk markers which predict the onset of such 
microvascular complications and can be an extremely useful therapeutic target 
for its prevention and care.  
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RIASSUNTO 
Presupposti dello studio: La retinopatia diabetica (RD), una delle principali 
cause di cecità nei paesi sviluppati, costituisce la più comune complicanza 
microvascolare del diabete mellito. Recenti studi hanno dimostrato che 
l’alterazione delle cellule gliali e la conseguente perdita di quelle neuronali si 
verificano prima che le lesioni vascolari siano clinicamente rilevabili. 
Scopo dello studio: Lo scopo dello studio è quello di ricercare biomarkers 
precoci di attivazione gliale nell’umore acqueo di soggetti diabetici non solo in 
presenza di segni clinicamente rilevabili di RD, ma anche in loro assenza. 
Materiali e metodi: In corso di intervento di cataratta, sono stati raccolti i 
campioni di umore acqueo di 34 pazienti così suddivisi: 12 soggetti sani, 11 
pazienti diabetici senza retinopatia diabetica e 11 con retinopatia diabetica non 
proliferante (di cui 5 senza edema maculare e 6 con edema maculare-ME). Prima 
dell’intervento, tutti i pazienti sono stati sottoposti a visita oftalmologica completa 
e tomografia a coerenza ottica di tipo spectral domain (SD-OCT) (Spectralis 
HRA+OCT, Heildeberg Engineering). Nei 34 campioni è stata effettuata la 
quantificazione delle proteine totali con metodo Bradford, di GFAP, AQP1 ed 
AQP4 con test ELISA e di 40 citochine infiammatorie con protein array. E’ stata, 
inoltre, effettuata la segmentazione degli strati retinici sulle scansioni SD-OCT.  
Risultati: I valori medi delle concentrazioni di GFAP, AQP1 e AQP4 nell’umore 
acqueo sono risultati significativamente più elevati nei soggetti diabetici rispetto 
ai controlli sani (p<0.05). L’incremento di GFAP e’ stato di circa 0.8 volte, di 
AQP1 di 1.1 volte e di AQP4 di circa 24 volte nei soggetti diabetici rispetto ai 
controlli. Le concentrazioni di GFAP, AQP1 e AQP4 sono risultate 
significativamente ridotte nei soggetti diabetici con ME rispetto ai diabetici senza 
ME, (Tukey Kramer post hoc, p<0.05). La concentrazione nell’umore acqueo, è 
risultata significativamente maggiore nei pazienti diabetici (con e senza RD) 
rispetto ai soggetti sani per le seguenti citochine: GFAP, AQP1, AQP4, IFNy, IL-
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1a, IL-1b, IL-3, IL-4, IL-10, IL-11, IL-17, TNF- α, TNF-ß, MCP1, MCP2, Eotaxin, 
Eotaxin 2, RANTES, sTNFRII, GM-CSF, IP-10, MIP1a, MIP1b. Lo spessore 
maculare medio di RNFL è risultato significativamente maggiore nei pazienti 
diabetici con RD e ME rispetto ai diabetici senza ME (con e senza RD) ed ai 
soggetti sani; lo stesso rapporto è stato osservato negli anelli interno ed esterno 
e nei settori superiore, inferiore e temporale. Lo spessore maculare medio di 
RNFL è risultato significativamente ridotto nei diabetici con RD e senza ME 
rispetto ai soggetti sani. 
Conclusioni: Sono stati riconosciuti nell’umore acqueo di soggetti diabetici 23 
diversi biomarkers proteici di attivazione gliale presenti sin dallo stadio subclinico 
della RD. Questi potranno essere utilizzati in futuro come marcatori di rischio per 
l’insorgenza di tale complicanza microvascolare e costituire degli utili bersagli 
terapeutici per la sua prevenzione e cura. 
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ABSTRACT 
Background: Diabetic retinopathy (DR), one of the leading causes of blindness 
in developed countries, is the major microvascular complication of diabetes 
mellitus. Recent studies have demonstrated that the alteration of glial cells and 
the consequent loss of retinal neuronal cells occur before the vascular lesions are 
clinically detectable. 
Purpose: To find early biomarkers of glial activation in the aqueous humor (AH) 
of diabetic patients both in presence and in absence of clinically detectable signs 
ofDR. 
Materials and methods: During cataract surgery, 34 patients’ AH samples were 
collected as follows: 12 healthy subjects, 11 diabetic patients without DR and 11 
diabetic patients with nonproliferative diabetic retinopathy (5 without macular 
edema-ME and 6 with ME). Before surgery, full ophthalmic examination and 
Spectral-Domain Optical Coherence Tomography (SD-OCT) (Spectralis 
HRA+OCT, Heildeberg Engineering) were performed in all eyes. The samples 
were analyzed for the quantification of total proteins by Bradford method, of 
GFAP, AQP1 and AQP4 by ELISA and of 40 inflammatory cytokines by protein 
array. Segmentation of retinal layers was also performed. 
Results: Mean concentration of GFAP, AQP1 e AQP4 was significantly 
increased in diabetics versus controls (324.44±262.54 pg/µg vs  182.34±114.44 
pg/µg for GFAP; 105.72±15.69 pg/µg vs 50.92±20.36 pg/µg for AQP1; and 
852.03+103.24 pg/µg vs 33.58±21.20 pg/µg for AQP4, p<0.05). GFAP showed 
an approximate 0.8 fold increase, AQP1 1.1 fold increase, whereas AQP4 about 
24 folds increase in diabetic patients versus controls. When we separately 
evaluated DR-no ME eyes vs DR-ME eyes, there was a significant decrease in 
GFAP, AQP1 e AQPR in DR-ME eyes versus DR-no ME eyes,  (Tukey Kramer 
post hoc p<0.05). GFAP and AQP1 showed even a slight fold decrease versus 
controls. AQP4/AQP1 concentration showed weak and non significant correlation 
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(Tau=0.21, p=0.3) between these biomarkers, despite the trend in increase. 
Following cytokines were increased in diabetic patients (with or without DR) 
compared to healthy subjects: GFAP, AQP1, AQP4, IFNy, IL-1a, IL-1b, IL-3, IL-4, 
IL-10, IL-11, IL-17, TNF- α, TNF-ß, MCP1, MCP2, Eotaxin, Eotaxin 2, RANTES, 
sTNFRII, GM-CSF, IP-10, MIP1a, MIP1b. RNFL mean thickness was significantly 
higher in diabetic patients with DR and ME compared to diabetics without ME 
(both with and without DR) and healthy subjects (respectively 37.3 μm vs 24.3μm 
vs 26μm 5μm vs 26.8μm), and the same significance was observed in the inner 
(33.4μm vs 22.0μm vs 25.0μm 24.3μm) and the external (54.7μm vs 36.7μm 
34.6μm 38.1μm) rings and in the superior (40.3μm vs. 26.1μm vs 29.2μm vs 
29.5μm), inferior (44.3μm vs 27.2μm vs 29.1μm vs 30.1μm) and temporal 
(26.3μm vs 16.8μm vs 18.9μm vs 18.0μm) sectors. RNFL mean thickness was 
significantly reduced in diabetics with DR and without ME compared to healthy 
subjects. 
Conclusions: 23 different biomarkers of glial activation have been recognized in 
the AH of diabetic patients even with subclinical DR. These proteins could be 
used in the future as risk markers of occurrence of DR and could provide useful 
therapeutic targets for its prevention and therapy. 
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INTRODUCTION 
1.1. Impact of diabetes mellitus on global health 
1.1.1. Epidemiology of diabetes mellitus 
Diabetes and its complications constitute one of the major health problems in the 
economically developed countries, and the exponential growth of its prevalence 
in the recent years has prompted the experts to describe it as a ‘global 
epidemic’.[1] Based on the data from 2010, its prevalence in the world is 
confirmed by approximately 284 million individuals with diabetes (about 6.4% of 
the global population), and the estimates show that in 2030 the number will rise 
to 439 million (about 7.7% of the global population); such increase will mainly 
concern the adult subjects in the developing countries, with an increase of 73% 
compared to the 20% increase in the developed countries.[2, 3]   
The prevalence of diabetes rises with age, reaching the 15.8% in the population 
over 65 years, and 18.8% in those over 75 years of age, without significant 
differences between the two sexes. [4] The recent estimates of the WHO (World 
Health Organization), moreover, show that diabetes is responsible for 2% of 
world deaths, causing more than 1 million deaths a year (a value, however, which 
is considered an underestimate).[5] If we focus on the situation in Italy, the ISTAT 
(The National Institute for Statistics) has estimated in 2008 the existence of 
known diabetes in 2.9 million of individuals (about 4.8% of the population), with 
an increase in the future years in accordance with the global trends. Such 
prevalence results greater in the South and in the islands, with about 5.8% 
individuals afflicted, followed by the center with 5.3% and the North with 3.9%.[5] 
The 2008 estimates show that in the Veneto region there are about 230 thousand 
subjects with known diabetes and that there is an average annual increase of 4-
5% of the total number of patients. [6]  
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1.2.1. Epidemiology of diabetic retinopathy 
 
Diabetic retinopathy (DR), one of the most common and severe diabetic vascular 
complications, constitutes the first cause of visual impairment and blindness in 
the adult working-age population in the developed countries.[1] It afflicts about 93 
million people in the world (about 2-3% of the global population) and is 
responsible for about 2.4 million cases of blindness. [7] In Europe, it afflicts about 
3% of individuals, with greater prevalence among people aged 60 and over in 
France and Germany.[7, 8] Italy and the Veneto region conform to these values. 
[9]  
According to the global estimates in 2012, 34.6% of diabetic patients present 
retinopathy, 7% of which in a proliferative stage, and 6.8% with macular edema. 
The prevalence is greater for Type 1 diabetes mellitus (DM) and the insulin-
treated Type 2 DM, and rises with the duration and the values of HbA1c, arterial 
pressure and cholesterolemia. [7, 9]   
While in patients with Type 1 DM the clinical symptoms of DR are present in 15-
20% of the cases 5 years after the diagnosis, in 50-60% of the cases 10 years 
after the diagnosis, and virtually in all the patients 30 years after the diagnosis, in 
patients afflicted by Type 2 DM such symptoms are present in 15-30% at the 
moment of diagnosis, in 50-70% 10 years after the diagnosis and in 90% after 30 
years. This can be explained by the fact that Type 2 DM is generally diagnosed 
much later compared to Type 1 DM , when its negative effects have had a longer 
period to act unobserved.[10] 
In the last thirty years, however, the incidence and the progression risk of such 
complications during the course of DM have diminished from values superior to 
90% to values inferior to 50%, thanks to stricter controls of the glycemia, the 
pressure and the cholesterolemia: recent American studies  show that the 
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percentage of Type 2 diabetic patients who reach normative values for these 
three parameters has risen from 30% to 50% between the years 2000 and 2006. 
Thanks to all this, the percentage of diabetic patients confronted with proliferative 
retinopathy, macular edema and visual deficit has significantly diminished in 
time.[11]  
Calculations show that if proliferative retinopathy is not treated, 50% of patients 
with retinal new-vessels are destined to become blind within 5 years, and 50% of 
patients with new-vessels of the optic disc become blind within 2 years.[11]  The 
three greatest risk factors for the appearance and the progression of DR are 
hyperglycemia, hypertension and dyslipidemia; to which one can add the duration 
of diabetes, pregnancy, genetic factors, cigarette smoke, alcohol, obesity and 
anemia. Antonetti et al. have recently suggested an association, uncertain as it 
might be, with serum prolactin levels, adiponectin and homocysteine, 
nonalcoholic steatohepatitis and the nocturnal apnea syndrome.[11]  
A singular aspect is represented by the fact that myopia, especially if high, 
appears to be a protection factor with respect to DR: the reduced blood flow in 
the myopic eye would, in fact, reduce the hematic extravasation of inflammatory 
molecules.[12] 
Even though retinopathy is the main ocular diabetic complication, it is not the only 
one. There are numerous studies, in fact, which demonstrate that, among the 
diabetic population, there is an increase in cataract incidence and its fast 
progression; such concept is valid for the cortical and subcortical posterior forms, 
while the association with nuclear forms appears to be without foundation. [10, 
13] In addition, there is an increase in the incidences of glaucoma, retinal 
hemorrhages, transient visual blurring and refraction defects.[14]  
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1.2. Retinal glial cells and the physiology of aqueous 
humour 
1.2.1. Retinal glial cells 
 
Figure 1. Schematic representation of the most important retinal cell types [11] 
 
The retina, which, with the exception of the optic disc, covers the entire inner 
surface of the eyeball, is a membrane assigned to transform the light stimuli into 
bioelectric impulses. It is structurally divided into an outer wall, constituted by the 
retinal pigment epithelium, and an inner one, represented by a multilayered 
nervous tunic (the neuroretina).[15, 16]  
The neuroretina is composed of five main types of neuronal cells (ganglion, 
bipolar, horizontal, amacrine and photoreceptor cells), glial cells (Müller cells, 
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astrocytes and microglia) and vascular cells (pericytes and endothelial cells).[16, 
17]  
The retinal glial cells comprise the macroglia, which in turn comprises the Müller 
cells and astrocytes, and the microglia. They function as neuronal structural 
support cells and represent connection elements between the neurons and the 
vascular cells, hence regulating neuronal nutrition, development and metabolism; 
they contribute, moreover, to the local inflammatory response. [17] Consequently, 
it is possible to understand how the glia, though it represents only one part of the 
retina, can influence the physiology of neurons and retinal vessels. Each cell 
underclass it includes, moreover, is markedly distinct from the others in 
distribution, morphology and physiology. [18] 
Retinal blood vessels are surrounded in its entirety by the glial cells’ processes: 
the deepest ones (located at the inner and the outer margins of the inner nuclear 
layer) are surrounded exclusively by the Müller cells, while the surface vessels 
(located at the interface between the vitreous humor and the retina, and in the 
ganglion cell layer) are surrounded both by Müller cells processes and the 
astrocytary ones. In both cases, glial and endothelial cells are separated by the 
basement membrane. [17] 
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1.2.1.1. Müller cells 
  
Figure 2. Müller cell in the human retina, as seen with an optical microscope. (A) 
Photographed immediately after isolation; (B) thawed after 12 months of 
cryopreservation.[19]  
 
Müller cells, present exclusively at the retinal level representing the main glial 
component of the area, extend almost through the entire thickness of the nervous 
retina, from the photoreceptor inner segments to the border with the vitreous. 
They fill out almost completely the extracellular space between the neuronal 
elements, and they constitute a great part of the total retinal volume, enveloping 
and separating different neurons, with the exception of synaptic junctions. Their 
cellular bodies, located in the inner nuclear layer (INL), develop a thick fiber 
directed towards the outside and one directed towards the inside. The first one, 
developing lateral processes which branch out in the outside plexiform layer 
(OPL), ends in the external limiting membrane (ELM), from which, for a very brief 
time, it develops microvilli in the space between the inner segments of rods and 
cones (called the fiber basket); their aim is to increase the cellular surface and to 
regulate the exchange of metabolites and ions between the cells and the 
subretinal space. The second fiber extends into the retinal nerve fiber layer 
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(RNFL), terminating in a process which comes into contact with the limiting glial 
cells in order to form the inner limiting membrane (ILM) between the retina and 
the vitreous humour. [16-18, 20-22]  
Müller cells are connected to blood vessels, astrocytes and neurons, and thanks 
to the fusion of the basal lamina on which they rest with perivascular cells and 
with the vascular endothelium, they participate in the formation of the blood-
retinal barrier and regulate its characteristics. They express different ion channels 
and co-transporters which rapidly remove ions, carbon dioxide and other 
metabolites released by neurons into synaptic spaces, which appear to be 
responsible for the association between neuronal activity and the blood flow 
regulation. These cells maintain the stability of the retinal extracellular space and 
cell plasma membranes through the regulation of retinal ion concentration (in 
particular potassium), the deactivation and the recycling of neurotransmitters, 
detritus removal, the regulation of glucose uptake through GLUT transporters, the 
glycogen storage and its conversion into lactate, the participation in the 
glutamate/glutamine cycle and the protection from glutamate excitotoxicity, and 
the retinoic acid synthesis starting with retinol. Finally they contribute to the 
development, metabolism and synaptic functioning of neurons, as well as to the 
mechanical support and the inflammatory response of the retina.[16-18, 20-22] 
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1.2.1.2. Astrocytes 
 
Figure 3. Human retinal astrocyte as seen on fluorescence microscope.[23]  
 
The astrocytes, getting their name because they are characteristically star-
shaped, are ubiquitous components of the central nervous system (CNS). At the 
retinal level, their cellular bodies are located inside the RNFL, while their 
processes envelop the neuronal cells of the ganglion cell layer (GCL).  
These cells almost certainly originate in a migratory process starting from the 
optic nerve, and, maintaining the same function, they constitute support elements 
for the axons of the ganglion cells. Their close association with the blood vessels 
of the inner retina hints at their participation in the constitution of the blood-retinal 
barrier and in its regulation. The endfeet of their processes come in contact with 
the adjacent capillaries, probably to allow the substance transport between the 
local circulation and the neurons. [16-18, 20] 
It is generally considered that the astrocytes carry out significant roles in the 
regulation of synaptic functions, e.g. in the extracellular ion regulation (particularly 
potassium), glycogen deposition, neurotransmitter capture and inactivation, the 
contribution to the inflammatory response and the regulation of ganglion axon 
growth. The astrocytes usually contain the particular proteins of the intermediate 
filaments: the immature ones are composed mainly of vimentin, while 
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subsequently the cells become rich in glial fibrillary acidic protein (GFAP). 
Different ionic channels for potassium, sodium and calcium are located on their 
surface, in order to maintain the equilibrium in the extracellular matrix, and they 
are able to produce proinflammatory cytokines and to replace the damaged nerve 
tissue. [16-18, 20] 
 
1.2.1.3. Microglial cells  
 
Figure 4. Human microglial cell as seen on fluorescence microscope.[24]  
 
Retinal microglial cells belong to the mononuclear phagocyte system 
(monocytes-macrophages) which, derived from bone marrow, migrate into CNS 
through blood, representing the most important component of the retinal innate 
immune system. These cells are situated both in the inner plexiform layer (IPL) 
and the outer one (OPL), and are endowed with branching processes, usually 
distributed in parallels on the retinal plane, which give them their star form.[18]  
The microglial cells usually monitor the extracellular matrix using their processes, 
but they do not migrate through retinal layers; furthermore they transiently come 
in contact with neural synapses, probably to monitor their functioning.  When 
activated, they undergo a morphological transformation into amoeboid cells with 
retracted and thickened branches, alter the expression of their surface molecules 
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and become mobile, migrating into damaged areas of the retina where they 
participate in the phagocytosis of the degenerating neurons and the cellular 
detritus, in the secretion of growth factors and cytokines and in the active 
remodeling of neurons and synapses. [16, 18, 20, 25, 25]  The microglia, 
therefore, helps contrast the retinal stress, but if the stress perseveres, they can 
cause a damaging and persistent inflammatory response.[21] 
 
1.2.3. Characteristics and physiology of the aqueous humour 
 
Figure 5. Schematic representation of the hydrodynamics of the aqueous humour. 
Produced by the nonpigmented ciliary epithelium (3), it leaves the anterior chamber 
through the trabecular meshwork and Schlemm’s canal (1) and in minimal part through 
the uvea (2).[26]  
The aqueous humour  (AH) is a clear, transparent liquid located in the anterior 
and the posterior chambers of the eye: while most of it (the four fifths) is located 
in the anterior chamber, a fifth is found in the posterior chamber where it is 
produced, at a velocity of about 2.2μl/min during the day and of about 1.2μl/min 
during the night, by the nonpigmented ciliary epithelium. However, as 
demonstrated by the qualitative and quantitative differences of proteins, ions and 
other solutes with respect to the plasma, the AH is not formed exclusively for a 
simple process of diffusion and filtration, but also for the active secretion 
operated by intraocular tissues, in particular by the ciliary epithelium. From the 
posterior chamber, the AH flows into the anterior chamber passing between the 
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iris and the crystalline lens, and from here a major part (85%) is drained, through 
the trabecular meshwork, into the Schlemm’s canal, to enter the blood flow 
through the episcleral venous plexus (trabecular pathway or the usual one); a 
small quantity (15%), however, reaches the choroid venous vessels through the 
uveal trabeculae (sclerouveal pathway).[15, 16]  
This ocular fluid plays an important role in maintaining certain functions, e.g. the 
ocular refraction, form and pressure; in addition, it supplies nutritive substances 
and the oxygen to the cornea, the crystalline lens and the trabecular meshwork, 
and it removes waste substances; finally, it contributes to the constitution of the 
local immune system.[27] 
From the physical point of view, the AH presents a specific weight which varies 
from 1003 to 1012, a refraction index between 1132 and 1137, and inferior 
viscosity and superior surface tension compared to the plasma. [26]  
From the chemical point of view, the AH is constituted by a complex mix of 
electrolytes, organic solutes, growth factors, cytokines and proteins which satisfy 
the metabolic needs of the nonvascularized tissues of the anterior eye segment. 
Among all of its components, it is important to remember sodium, potassium, 
chlorine, bicarbonate, glucose, urea, ureic acid, creatinine, enzymes such as 
cholinesterase, amylase, hyaluronidase, glycosidase and aldolase, as well as 
hyaluronic, ascorbic and lactic acids. The protein component is minimal, and it 
seems to derive from plasmatic filtration through fenestrated capillaries in the 
ciliary body.[16, 26]  
 
1.3. Classification of diabetic retinopathy 
In order to arrive at a successful treatment capable of significantly reducing the 
risk of severe visual loss, there is a strong need for an international classification 
system which would allow the proper assessment of the severity of DR and of the 
diabetic macular edema (DME).  The classification suggested by the Early 
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Treatment of Diabetic Retinopathy Study (ETDRS), based on the photographs of 
the ocular fundus, has resulted useful when applied in clinical trials, researches 
and publications, but is rather difficult to use in the everyday clinical practice.  
This is the reason for which, after several attempts by the single countries, the 
American Academy of Ophtalmology (AAO) has in 2001 initiated a project, 
concluded in 2003, which has enabled the creation of a new classification system 
of the severity of DR. [28] 
According to this international classification, diabetic retinopathy is divided in 5 
stages: absent, non proliferative mild, moderate, severe and proliferative (Table 
I). It may or may not be associated with macular edema which, if present, is 
classified in 3 stages: mild, moderate and severe (Table II): [28] 
 
Table I. International classification of diabetic retinopathy (AAO).[28] 
DR ABSENT Absence of retinal lesions 
DR NON 
PROLIFERATIVE 
MILD Microaneurysms only 
MODERATE 
More than only microaneurysms, but 
less lesions compared to severe NPDR 
SEVERE 
At least one of the following: 
 More than 20 intraretinal 
hemorrhages in each of the 4 
retinal quadrants  
 Definite venous beading in at 
least two quadrants   
 Intraretinal microvascular 
anomalies in at least 1 quadrant 
 
No sign of proliferative retinopathy 
DR PROLIFERATIVE 
At least one of the following: 
 Neovascularization  
 Vitreous/preretinal hemorrhage 
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Table II. International classification of diabetic macular edema (AAO).[28]  
MACULAR EDEMA ABSENT 
Absence of retinal thickening or hard 
exudates in the posterior pole. 
MACULAR EDEMA 
MILD 
Presence of thickening or hard exudates 
in the posterior pole but distant from the 
center of the macula. 
MODERATE 
Presence of thickening or hard exudates 
close to the center of the macula but not 
in the center. 
SEVERE 
Presence of thickening or hard exudates 
in the center of the macula. 
 
 
While in the early stages of the non proliferative form there are few visual 
symptoms, when we move into the advanced stages and into the proliferative 
form there can be significant visual loss and compromission of the central vision 
in the case of DME.  [29] 
 Non proliferative diabetic retinopathy (NPDR): 
The mild form of non proliferative diabetic retinopathy is characterized by the sole 
presence of microaneurysms which, though usually asymptomatic, may burst and 
cause intraretinal haemorrhages. Moving from the mild form into the moderate 
and severe ones, flame and dot-and-blot haemorrages, hard exudates, venous 
caliber changes and intraretinal microvascular anomalies (IRMA) appear, the last 
one considered a premonitory sign of the progression into the proliferative form. 
Microinfarctions at the nerve fiber level, known as cotton wool spots, indicate the 
presence of retinal ischemia caused by the obstruction of precapillary arterioles.  
 Proliferative Diabetic Retinopathy (PDR): 
Once ischemia develops, it may cause NVD - neovascularization of the disk, or 
NVE - neovascularization elsewhere, possibly followed by the new-vessel 
ruptures and the formation of retinal and vitreous haemorrhages. This may be 
followed by membrane constitution on the surface of the retina, the contraction of 
which may cause retinal detachment or the traditional macular edema, and 
consequently blindness. The most feared complication is constituted by the 
neovascular glaucoma: it is caused by the growth of new-vessels from the pupil 
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area to the chamber angle and may lead to blindness. Another possible 
complication is constituted by the rubeosis iridis.  
 Diabetic macular edema (DME): 
Macular edema may appear in any stage of diabetic retinopathy. The ETDRS has 
established that it may be considered clinically significant when one of the 
following occurs: 1) it presents a retinal thickening at or within 500μm of center of 
macula; 2) when there are hard exudates present in the same area associated 
with adjacent retinal thickening; or 3) when there is retinal thickening greater than 
1 or more disc diameter in size present which is within 1 disc diameter from the 
center of the macula.[30] 
 
1.4. Metabolic pathways implicated in retinal damage 
during the course of diabetes mellitus  
 
Figure 6. Metabolic pathways implicated in retinal damage during the course of diabetes 
mellitus. They damage both the neural and the vascular components of the retina.[31]  
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Even though the clinical studies  “Diabetes Control and Complications Trials” 
(DCCT) and “UK Prospective Diabetes Study” (UKPDS) have recognized 
hyperglycemia as the motivating factor for diabetic retinopathy, the mechanism 
through which the glucose provokes microvascular damages has not been 
entirely clarified.[32] There are different metabolic pathways involved: inside the 
cells, high glucose levels appear to stimulate polyol pathways, advanced 
glycation endproducts (AGEs), protein kinase C (PKC), poly-ADP-ribose 
polymerase (PARP), hexosamines, renin-angiotensin-aldosteron system (RAS), 
reactive oxygen species (ROS), inflammation and growth factors. [31, 32] 
 
 Polyol Pathway 
Usually a small fraction of glucose is metabolized through this pathway controlled 
by aldose-reductase enzymes (AR), which reduce glucose to sorbitol, and by 
sorbitol-dehydrogenase (SDH), which reduces sorbitol into fructose. In 
hyperglycemic conditions, such fraction increases, and, using the NADPH 
(nicotine adenine dinucleotide phosphate) as a cofactor, provokes a glutation 
decrease and an increase in oxidative stress, which in turn cause retinal 
damage.[31, 33-35] 
 
 AGEs Pathway  
Non enzymatic glycosylation consists in a chemical reaction which causes the 
glucose to bind to proteins, lipids and nucleic acids, and which, through a series 
of complex reactions, causes the formation of AGEs. Goh et al. have noticed in 
retinal vessels, in vitreous humour and in human serum, an increase of AGEs 
levels associated with the gravity of DR.[36] Stitt et al. have moreover 
demonstrated that the accumulation of AGEs in retinal pericytes, very important 
for microvascular homeostasis, is implicated in endothelial damage and in blood-
retinal barrier damage.[37] Finally, the Yamagishi group has shown how the 
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AGEs on one part increase, through ROS generation (free radicals/reactive 
oxygen species), the levels of VEGF (vascular endothelial growth factor), of 
MCP-1 (monocyte chemotactic protein-1) and of ICAM-1 (intercellular adhesion 
molecule-1) and, on the other, how they activate NF-kB (nuclear factor-kappaB) 
and NADPH-oxydase with the consequent ROS increase and the apoptosis of 
pericytes and other cells.[38-43] The AGEs disturb microvascular homeostasis 
through the interaction with their own receptors (RAGE), and they hold a central 
role in the inflammation, the neurodegeneration and the microvascular 
dysfunction.[31]  
 
 Protein Kinase C Pathway (PKC) 
Hyperglycemia induces the PKC pathway activation by increasing diacylglycerol 
(DAG) synthesis and other mechanisms. This leads to an increase in blood flow 
and vascular permeability, to the reduction in density of the basement membrane, 
to an expansion of extracellular matrix, to cellular apoptosis, angiogenesis,  
leucocyte adhesion and cytokine activation. [31, 32]  
 
 Poly-ADP-ribose polymerase (PARP) activation 
Drel et al. have noticed that when the nuclear enzyme PARP is activated in 
diabetic animal retina, it causes the DNA to rupture and it exacerbates the 
oxidative and nitrosative stress. In fact, the PARP activation provokes NAD+ 
(nicotinamide adenine dinucleotide) consumption, G3PD (glyceraldehyde 3-
phosphate dehydrogenase) inhibition and NFkB activation, all elements that 
induce an increase in ROS and nitrogen production, responsible for the retinal 
damage. [31, 44]  
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 Hexosamine pathway 
Giacco et al. have demonstrated that the hexosamine content in retinal tissue, 
both human and animal, is higher in diabetic subjects.[45] This is an extremely 
important result if we consider that Nakamura group had shown that the 
hexosamines alter the insulin signaling, contributing to the onset of DR.[46] 
 Renin-angiotensin system (RAS) 
The renin-angiotensin system, which regulates blood pressure and fluid balance, 
appears altered in diabetic patients, leading to microvascular dysfunctions.[47]  
Various studies have analyzed the components of these systems at the retinal 
level (Ang I -angiotensin I-, Ang II -angiotensin II-, prorenin, renin, ACE -
angiotensin-converting enzyme-, AT1R -angiotensin type 1 receptor-, AT2R -
angiotensin type 1 receptor-) and they have registered an increase in prorenin, 
renin and Ang II levels in the vitreous of the patients with proliferative diabetic 
retinopathy and with diabetic macular edema. [48-50] In addition to being a 
growth factor and to promoting cellular differentiation, apoptosis and extracellular 
matrix deposition, Ang II reinforces the harmful effects of the AGEs inducing 
RAGEs expression (AGEs’ receptors) in hypertensive eye: this points to a 
connection between the two systems.[31]  
 Oxidative stress 
Hyperglycemia causes the oxidative stress and determines cellular damage at 
the level of the retina. In the diabetic subject’s retina, the sources of reactive 
oxygen species have not been completely clarified yet, even though different 
studies evidence an increase in lactate, pyruvate, tricarboxylic acid and 
nitrotyrosine, in the consumption of cytosolic NADPH and in the stimulation of the 
glycolitic, AGEs, polyol, hexosamine and PKC pathways.[50, 51] Ulterior studies 
point at the participation of lipoproteic metabolism, the excess of excitatory amino 
acids, the alteration of growth factors, the activation of NADPH oxidase, the 
xantine-oxidase and the decrease of glutathione and antioxidant enzymes. [51-
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56] Apart from creating a vicious circle responsible for the production of ulterior 
EOS, the oxidative stress activates the other metabolic pathways responsible for 
the retinal damage. It is not entirely clear, however, if it has a primary role in the 
pathogenesis of diabetic complications in the early stages, or if it is only 
consequential of the tissue damage.[31]  
 
 Inflammation 
 
Different molecular and cellular alterations typical of inflammation processes 
have been found out in the retinas of diabetic animals and patients. Different 
evidence supports the idea according to which the DR is a manifestation of a 
chronic low-level inflammation in which different effectors, e.g. the cytokines and 
the leukocytes, are responsible for retinal damage.[31] Diabetic retinopathy 
presents many similarities to chronic inflammatory diseases: increase in vascular 
permeability, edema, infiltration of inflammatory cells, tissue destruction, 
neovascularization and retinal expression of inflammatory cytokines. Recent 
publications present strong evidence of an important inflammatory involvement 
even in the early stages of DR.[57-60] In addition, it has been demonstrated that, 
in both animals and patients with diabetes, the leukocytes, including monocytes-
macrophages (microglia), neutrophils and a certain number of lymphocytes 
adhere to retinal vascular endothelium. This temporally coincides with the 
compromission of the blood-retinal barrier, with the capillary occlusion and with 
the death of endothelial cells. The expression of adhesion molecules, particularly 
of ICAM-1 (intracellular adhesion molecule-1) and VCAM-1 (vascular cell 
adhesion molecule-1), appears increased in the diabetic subject’s retina and is 
connected to the increased leukocyte adhesion and the leukostasis.[61] 
If, in the healthy subject, the neurons express molecules which negatively 
regulate microglial activation, in diabetic subjects such regulation does not take 
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place, and the activated microglia produces cytokines and inflammatories. In 
addition, the high complement and the acute phase protein levels as well as the 
low levels of complement inhibitors represent a key moment in the damaged 
neurons’ phagocytosis.[11, 21]  
At the retinal level of diabetic mice and patients, different alterations have been 
identified: an increase in iNOS (inducible nitric oxide synthase), NO (nitric oxide), 
COX2 (cyclooxygenase-2), lipoxygenase, eicosanoids (including prostaglandins 
and leukotrienes), ICAM-1 and VCAM-1 on the surface of endothelial cells, PDGF 
(platelet-derived growth factor), VEGF, in IL-1, IL-6, IL-8, IL-13, MCP-1 
(monocyte chemotactic protein-1), MIP-1α (macrophage inflammatory protein-
1α), IP-10 (interferon gamma-induced protein 10), endothelin-1, TNF-α (tumor 
necrosis factor-α), RANTES (regulated normal T-cell expressed and secreted) 
and SDF-1α (stromal cell-derived factor-1). Furthermore, there was an increase 
in complement components such as C3, C5b and C9, and in molecules such as 
prothrombin, α1-antitrypsin, antithrombin III, coagulation factor XIII, Ang II, 
RAGEs (AGEs receptors) and NF-kB, while the PEDF (pigment epithelium-
derived factor) resulted decreased. All these alterations have a proinflammatory 
effect and they entail an increase of leukocyte adhesion and leukostasis, as well 
as a damage of the blood-retinal barrier and death of endothelial cells.[11, 58, 
62-67]  
This data, therefore, suggests that inflammation contributes to the development 
and the progression of retinopathy, as it is demonstrated by the fact that the 
intravenous administration of glucocorticoids and anti-VEGF improve the clinical 
picture.[11]  
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 Growth factors, neurotrophic factors and hormones 
 
Altered levels of certain molecules have been found in the diabetic subject, 
among which insulin, IGF-1 (insulin-like growth factor-1), aldosterone, 
adrenomedullin, GH (growth hormon), endothelin, VEGF, PEDF, FGF (fibroblast 
growth factor) and TGF-β (transforming growth factor-β). These elements are all 
responsible for both the structural changes of retinal vascularization 
(angiogenesis, ischemia, and increase in vessel permeability) and the 
progression of DR.[31] Neurotrophic factors such as insulin, PEDF, CNTF (ciliary 
neurotrophic factor), NGF (nerve growth factor), GDNF (glial cell line-derived 
neurotrophic factor) and BDNF (brain-derived growth factor), all of which appear 
altered in the diabetic subject, are responsible for retinal neuronal damage.[31] 
 
1.5. Clinical Progression of Retinal Damage during the 
Course of Diabetes Mellitus 
 
In the preclinical stage of DR, one witnesses the damage of endothelial cells, 
responsible for the integrity of the blood-retinal barrier, which are confronted by 
an accumulation of sorbitol with the consequent loss of osmotic equilibrium and 
of tight intercellular junctions; this leads to an increase in vascular permeability 
and the accumulation of extracellular fluid.[26, 68]  The noteworthy rarefaction of 
intramural pericytes, which have the capacity to synthesize TGF-β and to inhibit 
the proliferation and migration of endothelial cells, leads not only to the failed 
regulation of capillary perfusion and the partial weakening, but also to a 
neovascularization typical of the proliferative form.[68, 69] The thickening of the 
basement membrane and the increase of deposition of the extracellular matrix 
components are probably caused by the glycosylation of its constitutive 
molecules and/or by the reduction in production of proteoglycans, which 
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contribute to the hemodynamic alteration of retinal capillaries.[26, 68] The 
hematic and hemorheological alterations, on the other hand, consist in the 
increase in viscosity, caused by the reduced deformability of red blood cells, and 
in hypercoagulability, caused by the increase in platelet aggregation, fibrinogen, 
certain coagulation factors (VII and VIII), α2-globulin, and by the reduction of 
antithrombin III.[26] At this stage, first the autoregulation mechanisms are 
triggered, which subsequently they oppose the hypoxia caused by vascular wall 
lesions and other hemorheological alterations: among these, the first sign of 
compensation is constituted by vasodilation, more evident when found in macular 
circulation. With the advancing of the illness, nevertheless, the autoregulation 
capacities are no longer sufficient for the compensation of retinal metabolic 
necessities, and the already precarious conditions of the vessel wall are further 
aggravated. This leads to an ulterior thickening and structural alteration of the 
basement membrane, to the reduction of endothelial cells with tight junction 
rupture and to the disappearance of intramural pericytes.[26, 39, 70] 
The clinical stage of the illness therefore begins with the appearance of 
microaneurysms, hard exudates, vascular alterations and capillary occlusions. 
The microaneurysms are capillary dilatations caused by the swelling of their 
weakened walls or by endothelial gems which attempt to revascularize the retina; 
they can be identified as small red dots, are usually temporal with respect to the 
macula and can be saccular or fusiform in structure. Hard exudates, identified as 
yellowish white deposits in the external plexiform layer, are accumulations of 
lipids, proteins and microphages (microglia), which phagocytize such material 
and are the result of their extravasal precipitation, through capillary incontinence, 
beginning in the blood flow. The intraretinal hemorrhages are caused by the 
rupture of weakened capillaries and have different morphologies depending on 
their topographic localization: the surface ones are typically flame-shaped, as 
they are located between the axons within the nerve fiber layer, while the deeper 
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ones are dot-and-blot shaped due to the cell disposition just about perpendicular 
to the retinal surface. The pre-capillary arteriolar occlusion may cause retinal 
microinfarctions with consequent formation in the nerve fiber layer of cotton wool 
spots; the latter, blurred and off-white in colour, are caused by the swelling of 
nerve fiber terminations which follows the axonal flow halt determined by retinal 
ischemia. Capillary occlusions may also cause the intraretinal microvascular 
anomalies (IRMA), usually at the medium to extreme peripheral level of the 
retina, on the border with ischemic areas; they are represented both by retinal 
new-vessels and the dilatation of preexistent vessels, and would constitute a 
compensation attempt implemented through the opening of shunts with not yet 
occluded capillaries. Venous alterations are represented by irregularities and 
lumen duplications, and can assume a characteristic rosary-bead shape.[26, 70, 
71] 
 
 
Figure 7. Photograph of the ocular fundus of a patient afflicted by NPDR. Hard exudates (yellow 
arrow), microaneurysms (red arrow), cotton wool nodules (white arrow) and retinal hemorrhages 
(green arrow) are visible.[72] 
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From the established ischemic areas, VEGF, IGF-1 and FGF are liberated, and 
they determine a vascularization of the no longer perfused retinal zones. It initially 
concerns only the retinal thickness, but later on it can concern also the vitreous 
space, and more frequently the optic disc, due to the natural interruption of the 
inner limiting membrane.  Newly formed vessels present an anomalous wall 
constituted only by the endothelium, without a valid junction system or pericytes, 
and therefore tend to bleed frequently. Initially the new-vessels lack connective 
support, but in a brief time they become enveloped by a fibrous support tissue. 
Precisely for this reason the new-vessels bleed easily, but after the constitution of 
the fibrous component, there is a tendency towards closure and complications, 
e.g. the retinal detachment. [26] 
In each DR stage, the macular region may be involved, with edema, 
hemorrhages and hard exudates, which can lead to diabetic maculopathy. 
Macular edema, of particular danger to the visual prognosis when it strikes the 
foveal region, may be diffused through the entire thickness of the retina, or it may 
converge into lodges at the external plexiform layer level provoking the cystoid 
macular edema. It is caused by the loss of function of the blood-retinal barrier, 
with significant leakage of fluids, proteins and lipids into the sensory retina. 
Ischemic maculopathy is an ulterior aspect of the macular compromission, 
caused by capillary occlusion surrounding the fovea and leading to an extremely 
bad visual prognosis.[26, 30, 70] 
  
1.6. Physiopathology of Retinal Damage during the Course 
of Diabetes Mellitus 
 
For a long period of time, DR has been considered primarily a microvascular 
pathology caused by the direct effects of hyperglycemia and by the metabolic 
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pathways it activates.[73] Some recent studies have nevertheless demonstrated 
that retinal neurodegeneration, the result of a negative balance between the 
neuroprotector and neurotoxic factors, is present even before the development of 
microvascular damages detectable clinically in  ophthalmoscopic examination, 
which proves its participation in their appearance. It would therefore constitute an 
early event in the pathogenesis of DR and would anticipate the onset of 
microvascular alterations.[11, 21, 73-76] 
Already in 1961, Wolter et al. have observed in autoptic reports of diabetic 
subject the atrophy of ganglion cells and the degeneration of the inner nuclear 
layer, advancing the hypothesis according to which DR would not be solely a 
vascular pathology, but would precociously involve the neurons and the glia.[77] 
In 1962, the Bloodworth group described, in a study of 295 cadaver eyes, the 
degeneration of the inner plexiform layer and the ganglion cell layer, evidencing 
the presence of pyknosis and nuclear fragmentation, characteristics which are 
today widely recognized as typical of apoptosis.[78] In 1986, Scott et al. 
identified, in a study of the optic nerve in rats treated for 12 months with 
streptozotocin (a substance which induces diabetes), a reduction in the number 
of nerve fibers and an increase in the number of glial cells. [79] Lastly, in a study 
from 1998, the Barber group demonstrated, both in mice and in diabetic subjects, 
a high level of caspase-3 apoptosis mediated by the retinal neuronal cells, 
without noticing a similar significance in endothelial cells.[80] 
Neuronal damage and microvascular damage are interdependent and they 
strengthen one another’s effects: while the vascular hyperpermeability and 
occlusion compromise the integrity of neuronal and glial cells due to the 
penetration of inflammatory and cytotoxic molecules into the retina, the loss of 
function of the glial barrier and its increased expression of inflammatory cytokines 
and free radicals compromise the vascular functionality.[21] This relationship is 
explained by the fact that the vascular and the neuroglial components of the 
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retina come together to form the so-called ‘neurovascular unity’ of the retina, 
which is altered during the course of DM. It refers to the physical and biochemical 
relationship which exists between the neurons, the glia and the capillaries and to 
the close interdependence of these structures which permits the regulation of 
neuronal energy homeostasis and of neurotransmission. In addition, the 
interaction between the glial cells, neurons, endothelial cells and pericytes 
promotes the formation of the blood-retinal barrier which controls the passage of 
fluids and blood metabolites inside the nervous system parenchyma.  
In the internal retina, the neurovascular unity includes astrocytes, Müller cells, 
amacrine and ganglion cells, all placed in proximity of capillaries, a source of 
oxygen and nutrients, inside the GCL and on the borders of INL: the close 
connection of these structures is shown by the retinal blood flow regulation by the 
glial cells and by cellular metabolites. The neurovascular unity of the external 
retinal, instead, sees the photoreceptors and Müller cells paired metabolically in 
order to support the visual function through the diffusion of oxygen and nutrients 
by the choroidal vessels through the EPR.[11]  
 
Figure 8. Alteration of neurovascular unity during the course of diabetes. Image A shows 
the normal structure of neurovascular unity: pericytes and glial cells promote the 
formation of the blood-retinal barrier, creating favorable surroundings for neuronal 
functioning: the projections of microglial cells monitor this process. Image B shows the 
altered cell communication during the course of diabetes when there is an increased 
production of VEGF by the glial cells, an increased of inflammatory cytokines and the 
reduction of PDGF in pericytes; this contributes to the alteration of the blood-retinal 
barrier and, in certain cases, to angiogenesis.[11]  
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The idea according to which nervous damage precedes the vascular one is 
confirmed in the functional electrophysiological and psychophysical studies, 
which show that the alterations are present even before the microvascular 
damage becomes visible at the ophthalmoscopic exam. Such alterations consist 
in contrast sensitivity loss, altered colour perception and a failure of dark 
adaptation. It has been observed that in diabetic mice the oscillatory potentials in 
electroretinography (ERG), probably caused by neurotransmission in the internal 
retina, have extended peak latencies and/or reduced amplitudes, suggesting a 
compromised function of the internal retina. The motive for such alterations is 
unknown, but given that the oscillatory potentials are probably generated by the 
synaptic activity between amacrine cells and bipolar or ganglion ones, it might be 
traced to a neuronal transmission degeneration or to the combined loss of 
amacrine and ganglion cells.[81] 
Finally, it is necessary to remember that the particular structure of the retina is 
explanation enough for its sensitivity to diabetic disease: the demyelination of 
retinal axons, the reduced blood volume and the scarce number of cellular 
mitochondria are the key elements responsible for its vulnerability to 
hyperglycemic conditions.[11]  
 
1.6.1. Damage of retinal neuronal cells 
 
During the course of DR, apoptic cells have been observed in all retinal layers, 
suggesting the involvement of different types of neurons. [82] Numerous studies 
have, in fact, evidenced that diabetes, through metabolic pathway alterations or 
through neuronal support mechanisms, provokes the functional deficit and the 
loss of different types of cells: ganglion, bipolar, amacrine, horizontal and 
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photoreceptor. The data generally demonstrates an early dysfunction of the inner 
retina, followed by subsequent effects on the outer retina.[83]  
It is well known that, among nerve cells,  ganglion cells are the ones most 
affected by DM and that they are the first to face apoptosis, as shown by the 
increase in Bax (Bcl2-associated X protein), caspase-3, caspase-9, Bad (Bcl2 
antagonist of cell death), cytochrome c and AIF (apoptosis-inducing factor) in the 
inner retinal layers.[73] This is explained by the fact that they present a high 
metabolic activity and the noteworthy axon length exposes them to different types 
of stress, e.g. hypoxia, free radicals, mechanic compression, photooxidative 
damage.   
The retinal vascularization does not appear great in proportion, because there is 
the need for structural transparency for the proper photoreceptor functioning: the 
capillaries are in fact very thin, they have an elevated blood flow velocity and 
scarce intervascular connections. In addition, ganglion cells have a high 
tendency for the accumulation of metabolic end products such as free radicals, 
and, in spite of having greater antioxidant capacity compared to other types of 
neurons, they are nonetheless more vulnerable compared to Müller or endothelial 
cells. [84, 85]  
Meyer-Rüsenberg et al. have recently demonstrated that in diabetic subjects 
there is a dendritic structural remodeling at ganglion cell levels, which consists in 
an increase in length, density and number of terminations, and in a structural 
alteration of the axons which face a significant swelling.[86] 
In a study on diabetic mice from the same period, Gastinger et al. proved for the 
first time that even the amacrine cells are subjected to apoptosis, and that those 
which use dopamine and acetylcholine as neurotransmitters present a reduction 
in activity of enzymes tyrosin-hydroxylase and acetylcholinesterase. The same 
study evidenced a greater loss and susceptibility to apoptosis of cholinergic 
amacrine cells in the peripheral retina compared to the central one.[82] 
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Park et al. have observed that even the photoreceptors face apoptosis during the 
course of diabetic pathology, with the consequent alteration in colour 
distinguishing and a reduced blue-yellow contrast sensitivity. Given that the latter 
characteristic is also common in Parkinson’s disease, it would appear that it 
caused by a dopamine deficit.[82, 87] Photoreceptor apoptosis is exacerbated by 
the iNOS hyperexpression on behalf of the bipolar cells through a vicious circle 
involving glutamate-mediated exitotoxicity.[88] 
 
1.6.2. Damage of retinal glial cells 
Certain animal models have demonstrated that an important role in retinal 
neurodegeneration is carried out by glial cells, which constitute the earliest and 
the main target of chronic hyperglycemia. Metabolic and morphological 
alterations of these cells imply progressive neuronal suffering and loss, due to 
their important role in the mediation between retinal vessels and the neurons.[89, 
90] 
A great number of studies show that the low-level chronic inflammation 
contributes to retinal dysfunctioning during the course of diabetes mellitus.[58, 
62, 91] The high levels of neuroretinal inflammatory cytokines and of 
microvascular adhesion molecules would in fact lead to the accumulation of 
leukocytes and to the formation of neocapillaries in the retina. Some studies have 
found an altered cytokines expression not only at the vascular level, but also at 
the neuroglial one: if it is true that the retinal microglia carries out a primary role in 
this response, there is strong evidence that Müller cells and the astrocytes also 
express inflammatory cytokines in hyperglycemic conditions.[92] 
The Carrasco group has proven that both the apoptosis and the glial activation 
precede microvascular lesions, although it is still not known which one of these 
two events appears first.[93, 94] As a matter of fact, a study led by Tretiach et al. 
would corroborate the hypothesis according to which the retinal 
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neurodegeneration and, more particularly, the Müller cell damage would activate 
certain metabolic pathways which participate in microangiopathic processes and 
in malfunctioning of the hemato-retinal barrier, crucial elements of the 
pathogenesis of diabetic retinopathy.[95] 
Since both glial cells and the vascular endothelial cells are found in close 
association, Barber et al. suggested that the reactivity of the first ones is a direct 
consequence of the infiltration of glucose and the inflammatory blood agents into 
the nervous system parenchyma, and that, in its turn, the increased vascular 
permeability is supported by the release of certain glial factors with the 
consequent integrity loss by the hemato-retinal barrier.[96] 
The Müller cells and the astrocytes, besides supporting the synaptic activity, 
maintain the integrity of the blood-retinal barrier and regulate the vasoconstriction 
related to neuronal activity. They react, however, in different ways with regard to 
hyperglycemic damage: while by now it is clear that, during diabetes, the first 
ones face gliosis, functional activation and cell proliferation (with consequent 
increase of their numbers, even though there is an increase in cell apoptosis), 
few studies have analyzed the alterations that afflict the astrocytes, though it 
would appear that there is both loss and a functional alteration of these cells, 
previous to the events relative to Müller cells. [83] 
An interesting element consists in the fact that the Ly group has evidenced that 
glial alterations and tissue hypoxia are stronger in the peripheral retina than in 
the central one, suggesting a greater vulnerability with respect to diabetes. This 
may be explained with a structural difference between the two regions, even 
though it is necessary to carry out further studies in order to explain such 
phenomena.[83]  
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1.6.2.1. Alteration of Müller cells 
Müller cells result particularly susceptible to diabetes-induced damage and are 
recognized today as key elements in the onset and the progression of diabetic 
retinopathy.[97]  
These cells react to hyperglycemic condition by facing a reactive gliosis process 
characterized by three non-specific responses: hypertrophy, cellular proliferation 
and an increase in intermediate filament proteins nestin, vimentin and GFAP 
(glial fibrillary acidic protein). The reaction already possesses both cytoprotective 
and cytotoxic effects with respect to retinal neurons: mostly in the initial stages of 
diabetic illness, it is neuroprotective and may be interpreted as an effort to limit 
the extension of tissue damage; successively, however, it contributes to 
neurodegeneration and impedes tissue restoration and normal 
neuroregeneration. [98] 
 
Figure 9. Müller cell gliosis in rat’s retina 6 weeks after the onset of diabetes. In controls, 
GFAP is expressed only by astrocytes in GCL, while nestin is localized exclusively in 
blood cells inside the vessels (arrows), and Kir4.1is found prevalently around blood 
vessels (arrows) and on the inner and outer limiting membrane’s level (arrow heads). In 
diabetics, GFAP is expressed by Müller cells throughout the entire retinal thickness, while 
nestin is localized both there and in leukocytes infiltrated in the ONL and Kir4.1 is 
redistributed on the entire length of Müller cells. GCL: ganglion cell layer, IPL: inner 
plexiform layer, INL: inner nuclear layer, ONL: outer nuclear layer.[98]  
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The neuroprotective effect involves different mechanism which entail the 
alteration of potassium channels, excess glutamate re-uptake, antioxidant 
release (e.g. glutathione, pyruvate, α-ketoglutarate, mettallothionein, lysozyme, 
ceruloplasmin, and heme-oxygenase), production of growth factors and 
neurotrophic factors (in particular GDNF, FGF, VEGF, PEDF and TGF-β), 
cytokine and erythropoietin secretion, ascorbate reduction and the 
dedifferentiation of Müller cells in stem cells.[98] 
Nevertheless, with the protraction of detrimental stimuli, Müller cells increase the 
expression of growth factors, which become harmful, and secrete 
proinflammatory cytokines, which recruit the monocytes/macrophages (microglial 
cells) and neutrophiles in the damaged area, which in turn release the oxygen 
reactive species and cytotoxic cytokines.[99] Other alterations involve those of 
aquaporins, carbonic anhydrase and glutamine-synthetase and of the production 
of proteins involved in glycolysis; this comprises the damages of glia-neuron 
interaction and acid-base and ion homeostasis, contributing to the development 
of edema, neuronal hyperexcitability, glutamate toxicity and the increase in 
sensitivity with respect to stress stimuli, along with neuronal dysfunction and 
loss.[98] 
Müller cells, having the ability to dedifferentiate themselves into cells which show 
similar characteristics to pluripotent retinal progenitors, or into stem cells, cause 
an instability in the removal of neurotransmitters and in the homeostasis of 
potassium and water, with the consequent functional decoupling with respect to 
neurons. Müller cells’ lack of support, moreover, may have an additional effect on 
neuronal dysfunction and loss, increasing the susceptibility to stress stimuli in 
pathological retina: these cells have a leading role in the regulation of osmotic 
equilibrium, one of the main mechanisms involved in the development of diabetic 
macular edema, regulating the water and potassium flows through cellular 
membranes through AQP4 and Kir4.1,.[98, 100] 
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Müller cells may reenter the proliferative cycle, developing glial scarring, which 
impedes tissue repair and neuroregeneration through inhibitory molecule 
expression on the surface of reactive glial cells,.[99]  
Diabetes, furthermore, induces the activation of the apoptotic cascade in these 
cells, as well as their swelling caused not only by the alteration of potassium 
channels but also by the alteration of proinflammatory enzymes. [101, 102] 
Finally, it is necessary to consider that the compromission of the hemato-retinal 
barrier consequent to the malfunctioning of Müller cells entails an increase of 
vascular permeability as well as the extravasation into the perivascular space of 
numerous sieric components, which stimulate the proliferation of the cells.[100] 
 
1.6.2.2. Astrocyte alteration 
Rungger-Brändle et al. have noticed that, during the course of diabetes mellitus, 
the retinal astrocytes, even though gliosis alters them morphologically so that 
they divide and extend their processes, reduce in number through apoptosis, 
contrary to what happens to the Müller cells.[103] In spite of the fact that the two 
types of cells share certain functions, the opposite reaction to hyperglycemic 
conditions emphasizes the differences inherent in the process of their activation 
and in their metabolism: it has been observed, in fact, that the expression of 
sodium bicarbonate cotransporters is different and that the elective glycogen 
accumulation in Müller cells expresses a different reworking of this molecule. 
[104, 105] Since the astrocytes are preferentially in contact with ganglion cells 
and retinal vessels, it is moreover possible that they are influenced by their 
extracellular surroundings in a different way compared to Müller cells, which in 
turn extend through the entire retina. [103] 
A recent study carried out by the Bringmann group indicates that astrocyte 
alterations usually take place early in course of diabetic pathology and are 
accompanied by the inner retinal hypoxia and by the dysfunction of ganglion 
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cells, while the Müller cell gliosis and the compromission of nerve cells appear 
later.[98] Since astrocytes are usually recognized as the modulators of neuronal 
and vascular function, they seem to carry out a significant role in the 
development of tissue hypoxia, in vascular alterations and in the dysfunction of 
ganglion cells. Their close proximity to retinal vessels and to the ganglion cell 
layer, as well as their role in the formation of blood vessels, neurovascular 
coupling and the modulation of pathological neovascularization, makes them  
critical modulators of early retinal changes during the course of diabetes.[83] 
Mogi et al. have in fact demonstrated that the reduced astrocyte communication 
and the diminished expression of proteins forming the retinal tight junctions, 
characteristic for hyperglycemic conditions, seem to be connected to neuronal 
dysfunction.[106] 
Ly et al. have recently observed that, in the periferal retina of mice, already four 
weeks after the onset of diabetes, a connexin reduction can be found. This would 
not only reflect a reduction in the formation of tight junctions  and the consequent 
compromission of astrocyte communication, but also the reduction of the 
apoptosis-facing astrocytes. They have, moreover, evidenced that the early 
astrocyte loss is accompanied by the reduced GFAP expression by these 
cells.[83]  
 
Figure 10. Alteration in the number and expression of GFAP and connexin in rat with 
early diabetes (4 weeks after the onset). The astrocytes, seen with the fluorescence 
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microscope, have been marked with antibodies for connexin-43 (in green) and for GFAP 
(in red): notice the reduction in cell number and expression of the two proteins in 
diabetics (B) compared to healthy controls (A). The bar corresponds to 50 μm.[83] 
 
1.6.2.3. Alteration of microglial cells 
In the healthy retina, the microglial cells are not dormant as it was once thought, 
but, thanks to their processes, they constantly supervise the different retinal 
regions even without actively penetrating the retinal layers. The insults which 
cause neuronal apoptosis and degeneration induce the recruitment of microglial 
precursors originating in blood, as well as their activation and rapid migration 
towards the damaged region, with concomitant transformation from a branched 
form to an amoeboid one. There is a consequent accumulation of microglial cells 
around the dying cells in nuclear layers and in subretinal space, as well as a 
depletion of these cells in the rest of the retina. [107] 
 
Figure 11. Schematic representation of the three phases of microglial activation. (A) In 
the neuroretina the microglia populates chiefly the inner and the outer plexiform layers. 
(B) Retinal insults rapidly activate the microglia. (C) Microglial cells which are activated 
and/or derived from blood precursors migrate into lesion sites where they acquire a 
amoeboid morphology. Such cells may have a protective or a damaging effect based on 
the immunological phenotype and on the surrounding cytokines. RPE: retinal pigment 
epithelium; OS: photoreceptor outer segment; IS: photoreceptor inner segment; ONL: 
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer. [107] 
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Certain studies have shown that the retinal inflammation during the course of 
diabetes mellitus is a relatively early event, and that is precedes the vascular 
dysfunction and the neuronal degeneration. 108] Microglial activation has been 
recognized as the main responsible for the initial inflammatory response, even 
though the exact mechanism through which it releases inflammatory cytokines 
remains in the dark.[109]  
The activated microglia secretes cytokines and other proinflammatory molecules 
used for the phagocytosis and the destruction of damaged cells, as well as for the 
triggering of reparation processes which lead to the formation of glial scars. If it 
remains in an activated state, however, the cytokines may damage the 
neighbouring cells, particularly the neuronal and the vascular ones, leading to the 
onset of other retinal pathologies, such as the retinal degeneration and the 
glaucoma.[109] In compliance with this thesis, numerous histopathological 
studies done on both animals and humans have evidenced the activation of 
microglial cells, as well as the presence of different inflammatory molecules 
secreted by the microglia, usually associated with neuronal and endothelial 
death. [103, 110-113] 
Despite the fact that the mechanisms at the base of microglial activation remain 
unknown, it has been supposed that the glycated albumin, accumulated in the 
inner retinal layers due to increased vascular permeability, and probably partially 
produced on local level, can provoke these cells to produce inflammatory 
molecules. This would induce the TNF-α secretion in microglia as well as the 
localized secretion of proinflammatory cytokines, growth factors and other 
bioactive molecules through the connection to different cellular types and various 
metabolic pathways, carrying out important roles in the onset and the progression 
of diabetic retinopathy.[109, 114] 
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M-CSF (macrophage colony-stimulating factor), expressed by neurons, 
astrocytes, endothelial cells and the very microglial cells, seems to have a key 
role in the regulation of the activation, the proliferation and the migration of the 
microglia: Liu et al. have demonstrated that even at the onset of diabetic 
pathology there is an increased retinal expression of M-CSF and M-CSF-R, its 
specific receptor present on microglial cells. The same group has observed that 
M-CSF exclusively induces a microglial proliferation, whose activation through 
glycated albumin results necessary in order to create an inflammatory response. 
[114] In addition, Langmann et al. have observed that the M-CSF-R 
hyperexpression entails a hyperproliferation of these cells and an increased 
expression of di iNOS, IL-1β, MIP-1α, IL-6 and M-CSF on their part. [115] 
The Zeng group, investigating microglial activation around retinal capillaries, has 
detected the so-called ‘microglial perivasculitis’, supposing that it originates in the 
infiltration of hematic inflammatory molecules through vascular walls, but also in a 
local primary process. The same group has evidenced the nearness of 
perivasculitis to neuronal cells, especially to the ganglion ones, underlining the 
ways in which the inflammatory reaction afflicts these cells from the very 
beginning. The release of cytokines and microglia molecules such as TNF-α, IL-
1β, NO and VEGF provoke the diffusion of the inflammatory process through the 
entire retina, exacerbating the increase in vascular permeability and in neuronal 
damage, thus creating a vicious circle. [110] 
 
Figure 12. Activation of the retinal microglia in a rat 4 weeks after the diabetes onset. 
Microglial cells are evidenced with the specific marker OX-42 (brown). In diabetics, there 
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is an increase in brown stains and in digitiform protrusions inside the ganglion cell layer 
(marked by the arrow) [90] 
 
1.7. Biomarkers of glial activation during the course of 
diabetic pathology 
1.7.1. Aquaporins  
The aquaporins (AQPs) are a family of integral membrane proteins with low 
molecular weight (about 30kDa/monomer) arranged in tetramers, which mediate 
the transcellular flow of free water and in some cases of gas and solutes. The 
isoforms 3, 7 and 9 are called ‘aquaglyceroporins’ because of their ability to 
transport also glycerol and other small solutes, such as ions, urea and lactate. 
The aquaporins have a crucial task in the preservation of the ion- and osmotic 
equilibrium inside the CNS, neuroretina included, in response to different osmotic 
gradients and hydrostatic pressures. [116] 
Tenckhoff et al. have demonstrated that the human retina expresses the mRNA 
of all the 13 isoforms (AQP0-12) identified in mammals. [117] The 
immunohistochemical studies carried out so far, however, have confirmed the 
expression of only few aquaporins in the eye of a healthy mammal (mouse, pig, 
horse, rabbit and man): 
 AQP0: in the lens epithelium and in neuroretina (at bipolar cell, amacrine 
cell and ganglion cell levels); 
 AQP1: in the endothelium of the cornea and the iridocorneal trabecular 
meshwork, in the epithelium of the cilliary body, the lens and the iris, in 
the RPE and in the neuroretina (in amacrine cells and photoreceptors); 
 AQP3: in the conjunctival and the corneal epitheliums and in RPE; 
 AQP4: in the ciliary epithelium, the lachrymal gland epithelium and the 
neuroretina (in Müller cells and astrocytes);  
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 AQP5: in epitheliums of lachrymal glands, the conjunctiva and the lens.  
 AQP6: in the neuroretina (Müller cells); 
 AQP9: in the neuroretina (amacrine and ganglion cells). 
 It is therefore understood that so far only some isoforms (AQP0, AQP1, AQP4, 
AQP6, AQP9) have been detected in the neuroretinal level of a healthy 
mammal.[118-130] The presence of these proteins has been confirmed in most 
cases inside the human eye as well. [131-141] Among the various aquaporins, 
AQP1 and AQP4 have received the greatest attention, because it has been 
demonstrated that, in the CNS, they not only facilitate the bidirectional flow of free 
water through the cerebral parenchyma, but that they also modulate the neuronal 
excitability and potentiate the astrocyte migration; lastly, they seem to be involved 
in the production of aqueous humour. [116] 
In normal conditions, the fluids that accumulate inside the neuroretina and in 
subretinal space are reversed into the blood via transcellular transport 
osmotically coupled with the flow of various molecules, especially ions, at the 
level of the retinal pigment epithelium, of Müller cells and of astrocytes. The 
aquaporins facilitate the transcellular water flow: AQP1 in RPE and AQP4 in 
astrocytes and Mϋller cells. The last two cell types regulate the flow of potassium 
released by active neurons, which would, if present in excess on the extracellular 
level, induce neuronal hyperexcitability.  
Above all, Müller cells express different channels for this ion, the most important 
ones being the Kir2.1 (inwardly rectifying potassium 2.1), expressed in the parts 
of the membrane contiguous to neuronal cells, and the Kir4.1 (inwardly rectifying 
potassium 4.1), expressed in the parts surrounding the blood vessels, in both 
retinal membranes and in the parts facing the vitreous (i.e. in terminal parts of 
thick fibers). Kir2.1 mediates a unidirectional potassium flow directed at the inside 
of Müller cells, while the Kir4.1 mediates bidirectional currents between the 
extraretinal tissue and the cells themselves. The co-localization of Kir4.1 and 
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AQP4 around the vessels, at the retinal limiting membrane level and at the border 
with the vitreous, and the co-localization of Kir2.1 and AQP4 at the border with 
the neuronal cells, indicate the coupling of the free water transport with the 
potassium transport, through which Müller cells maintain the homeostasis inside 
the inner retinal layers. [102, 140, 142, 143] It is, therefore, supposed that the 
aquaporins and the potassium channels cooperate at maintaining the balance of 
this ion inside the retina: during elevated neuronal activity, these molecules would 
mediate the potassium and water uptake by the Müller cells, as well as the 
successive outflow into the vitreous and into the vessels. Nagelhus et al. have 
moreover observed that the microvilli are the only parts of these cells in which the 
two types of channels show a clear difference of expression, a fact which seems 
to have great functional importance: the combination of a low water permeability 
and a high potassium permeability would, in fact, protect the subretinal space 
from the inappropriate changes in volume. [142] Recent studies conducted on 
mice have demonstrated that diabetes alters not only the expression but also the 
localization of aquaporins.  
The Iandiev group has observed that, in healthy mice, the AQP4 expressed by 
Müller cells and astrocytes, is present in the most internal layers of the retina, 
mainly around retinal vessels (both surface and deep ones), while the AQP1, 
expressed by amacrine cells, photoreceptors and RPE, is located in more 
external retinal layers. In diabetic mice, however, a strong additional expression 
of AQP1 has been noticed inside the Müller cells in the internal layers, as well as 
the aquaporin conversion from isoform 4 to isoform 1 in the portion of the 
membrane surrounding the surface vessels in the retina, while the AQP4 remains 
expressed in the portions adjacent to more profound vessels. The significance of 
this change remains uncertain, although the presence of a similar alteration in the 
retina after a transitory ischemia suggest that it may well mirror the conditions of 
scarce profusion in diabetic mice.[126] Considering the total expression levels of 
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the two aquaporins in diabetic mice, various studies agree on the increase of 
AQP1, while there are contrasting opinions with respect to AQP4. [116, 121, 144, 
145] While the Zhang and Cui groups claim that AQP4 has increased, probably in 
response to the edema, the Curtis group and the Fukuda group affirm that there 
is a reduction of this channel, and the Gerhardinger group has not noticed any 
variation.[97, 121, 146-148] 
 
 
Figure 13. The alterated expression of AQP4 and Kir4.1 provoked by diabetes in the 
mouse retina. (a) In controls Kir4.1 and AQP4 are expressed at the membrane level by 
the Müller cells which surround the vessels (arrows) and in both limiting membranes 
(arrow heads); AQP4 is moreover localized in Müller cell membranes in both plexiform 
layers and in the ganglion cell layer. (b) In diabetic mice, the expression of Kir4.1 around 
the vessels and the limiting membranes results absent. (c) Deep vascular plexus inside 
the inner nuclear layer. The vessels are surrounded by AQP4 and Kir4.1 in controls and 
only by AQP4 in diabetic animals. GCL: ganglion cell layer; IPL: inner plexiform layer; INL 
inner nuclear layer; ONL: outer nuclear layer. [102] 
 
The Bringmann and the Iandiev groups have observed that, when Müller cells’ 
damage is present, in the initial phases there is a failure in the coupling of water 
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and potassium channels in the inner layers caused by the redistribution and the 
down-regulation of Kir4.1 at the levels of the vessels, the limiting membranes and 
those confining the vitreous, while there are unchanged expressions of AQP4 
and Kir2.1 at the interface with neuronal cells. This causes an unchanged 
potassium uptake by the Müller cells but a compromission of its release, with 
consequent accumulation and increase of the osmolarity of cytoplasm and  the 
glial swelling which could contribute to the neuronal death and the retinal edema.  
[100, 102, 126] The AQP1 hyperexpression could therefore be explained as a 
compensation attempt for the osmotic gradient between the blood and the retinal 
tissue, a hypothesis that seem to be supported by the contemporaneous increase 
in GFAP and the creation of apoptotic ganglion cells. [116, 126]   
The reduced Kir4.1 expression in Müller cells would therefore be the responsible 
for the massive retinal neuronal loss. In addition, ion imbalances caused by the 
potassium channel alteration would contribute to the glutamate accumulation in 
the extrasynaptic ambient due to its failed removal, and this would lead to the 
compromission of the normal negative membrane potential.[100] 
The Cui group, however, has recently observed an increased AQP4 expression 
in diabetic mice 48 hours after the streptozotocin injection. The same group has 
highlighted the ways in which the suppression of this channel’s expression 
worsens the retinopathy through the aggravation of the inflammatory response 
and the increase of proinflammatory molecules such as IL-1β, IL-6, ICAM-1 and 
VEGF, and the increase of leukostasis. [147] 
It has been recently suggested that even the AQP4-AQP1 shift in the astrocytes 
may lead to the imbalance of water and other solutes between the astrocytes and 
the ganglion cells, with consequent increase of the apoptosis of the latter. [121] 
The Iandiev and Holborn group have observed that AQP6 is selectively 
expressed in the membranes of Müller cells surrounding the synapse at the OPL 
level. [122, 144] The second group has furthermore noticed a reduced 
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expression of this channel in diabetic mice, which is similar to what happens in 
the blue-light-induced damage. Given that the AQP6 has a low permeability with 
respect to the water, and that it prevalently functions as a passage channel for 
ions and hydrophilic molecules such as glycerol and urea, it has been speculated 
that it regulates the ion concentrations on the level of the OPL synapses: its 
reduced expression would therefore imply an altered synaptic activity and the 
consequent alteration in retinal functionality. [144] 
In addition, Hollborn et al. have evidenced the expression in diabetic mice of 
AQP5, AQP9, AQP11 and AQP12 inside the RPE, usually not located there. 
AQP5, AQP11 and AQP12 could potentiate the water transport through the RPE, 
in an attempt to contrast the subretinal edema. The AQP9, able to transport 
water, ions and small solutes like lactate and glycerol, could facilitate the 
elimination of the excess lactate; it has to be noted, however, that its expression 
at the neuroretinal level remains unchanged during the course of diabetes.[144] 
 
 
Figure 14. Variation of mRNA expression of different aquaporins in the diabetic rat retina 
determined by the RT-PCR. Significant difference between diabetic rats and the controls: 
*p<0.05; **p<0.01. Significant difference between the neuroretina and the RPE: •p<0.05; 
••p<0.01.RPE: Retinal pigment epithelium. [144] 
 
Lastly, Fukuda et al. have demonstrated an increased AQP0 expression in the 
ganglion cells’ axons in the diabetic mice retina. The fact that such alteration has 
not been registered either during the course of ischemia or during the course of 
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glaucoma, seems to suggest that it is specific to diabetes, even though further 
studies need to be conducted in order to confirm this theory. [121] 
 
1.7.2. Glial Fibrillary Acidic Protein  (GFAP) 
 
The GFAP (glial fibrillary acidic protein) is usually expressed only by astrocytes, 
and is therefore detectable only in RNFL and GCL, while it results completely 
absent in Müller cells. [83, 97-99, 101] The GFAP increase, a common marker for 
reactive gliosis, is an early sensor for retinal stress preceding the microvascular 
damage. [99, 149] 
While it has been ascertained by now that Müller cells face an increased GFAP 
production during the course of diabetes, there are some works which express 
contrasting opinions regarding the GFAP expression in the astrocytes. [92, 150] 
In past, the Lieth group had shown that there was an increased production of 
such protein in both cell types, while the Rungger-Brändle group had not found 
significant differences in the astrocyte numbers and the GFAP production in 
diabetic mice compared to the healthy ones.[103, 151]  
Subsequently, however, Barber et al. have demonstrated that in diabetic mice 
there is an increased GFAP production only in Müller cells, and that this event is 
preceded by its reduced expression on the part of the astrocytes: in this way, the 
immunoreactivity of this protein is no longer limited exclusively to the RNFL and 
GCL layers, but it extends through the entire thickness of the neuroretina. The 
same authors have detected that the remarkable reduction of this protein in 
astrocytes disappears soon after the administration of insulin. [96] 
The data presented by the Barber group is considered the most correct today, 
since he used immunohistochemical techniques applied to fresh histological 
samples and not to frozen ones (in which the tissue structure is changed): this 
has allowed for a more accurate cellular distinction.[96]   
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In addition, the recent demonstration by Kumar et al. of the GFAP increase and 
cellular hyperplasia in astrocytes in the early stages of diabetic retinopathy can 
be explained by the fact that the apoptosis and the dysfunction of these cells are 
still not enough to reduction of the levels of this protein. [152] 
 
Figure 15. Variation of GFAP expression in astrocytes and Müller cells in rat retina 4 
months after the onset of diabetes, with or without the 48 hour insulin treatment.(A) 
Intensely GFAP immunofluorescent astrocytes in the healthy mouse. (B) The 
immunofluorescence for GFAP is almost imperceptible in the diabetic mouse. (C) The 
immunofluorescence for GFAP is elevated 48 hours after the insulin treatment. (D) Müller 
cells in the healthy mouse do not have immunofluorescence for GFAP. (E) Müller cells in 
the diabetic mouse are intensely immunoreactive for GFAP. (F) after the 48 hour insulin 
treatment, the immunoreactivity for GFAP is reduced. The bar corresponds to 50 μm.[96] 
 
1.7.3. Inflammatory Molecules 
Müller cells, astrocytes and microglia are the cells of the local innate immune 
system. Under stress, they become active and produce proinflammatory 
cytokines and growth factors in order to reconstruct the tissue homeostasis, but 
in chronic pathologies like diabetic retinopathy, the persistent inflammatory 
response leads to cellular death or damage.  
Liou et al. have recently confirmed that the microglia faces the activation already 
at beginning of diabetic pathology, producing a wide range of proinflammatory 
cytokines, such as IL-1β, IL-3, IL-6, TNF-α, and other inflammation mediators like 
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ROS, glutamate, VEGF, lymphotoxins, metalloproteinase and NO. These 
mediators induce the expression of adhesion molecules (I-CAM and V-CAM) in 
vascular cells for lymphocytes and monocyte-macrophages, cellular apoptosis, 
leukocyte infiltration and the weakening of the hemato-retinal barrier. [59] 
The Langmann group has detected that the microglial cells are the responsible 
for an increased retinal production of iNOS, IL-1β, MIP-1α, IL-6 and M-CSF.[115] 
In addition, Shelton et al. have evidenced an increase in IL-1β, IL-6, IL-8, IL-13, 
IP-10, ICAM-1 and NO in Müller and endothelial cells during the course of 
diabetes, confirming their participation in the inflammatory process. [153] 
Led by the fact that IL-1β is the main cytokine to trigger the neuroinflammatory 
cascade, Liu et al. have also considered its role in the amplification of the 
inflammation itself. This study has, in fact, highlighted that the IL-1β secretion 
begins in the vascular endothelium as the direct consequence of chronic 
hyperglycemia, which stimulates the endothelial, macroglial and microglial cells 
via the autocrine and the paracrine pathways, which do not respond only with 
activation signals, but also with the strengthening of IL-1β synthesis, thus exalting 
the inflammatory process. [154] 
Besides the already mentioned inflammatory mediators, it is well known that 
many other mediators are expressed inside the retinal tissue during the course of 
diabetes, since it is clear by now that inflammation has an essential role in 
diabetic retinopathy. [62] It is generally thought that the microglial cells also 
indirectly intervene in their production, due to their ability, via the production of 
mentioned molecules, to behave as chemioattractants towards the other 
leukocytes, especially the neutrophils and lymphocytes, which can strengthen the 
inflammatory process. The analysis of retinal tissue, aqueous humor and the 
vitreous have in fact detected the presence of other molecules besides those 
already mentioned, such as TNF-α, MCP-1, RANTES, IL-10, IL-12, MCP-1, MIP-
1β, PDGF e SDF-1α.[62, 155, 156] 
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1.7.4. Glutamate and GABA (gamma-aminobutyric acid) 
By now it determined that glial cells have an essential role in the regulation of 
nerve activity and in the synaptic transmission in the retina thanks so the release 
of so-called gliotransmitters, which have both an excitatory and an inhibitor effect 
on the surrounding neurons. Among the various neuroactive molecules released, 
glutamate and GABA have the task ofmodulating the neuronal activity in cellular 
products: the excitation is mediated especially by glutamate, while GABA causes 
neuronal inhibition. [157, 158] 
In the healthy retina, Müller cells have an important role in the degradation of the 
glutamate and GABA neurotransmitters, contributing to the proper functioning of 
synaptic terminations: the glutamate, released on the extracellular level by the 
neurons, is caught by Müller cells through the GLAST transporter (glutamate 
aspartate transporter); here it is rapidly converted into glutamine and led back to 
the neurons as a precursor of glutamate and GABA. [158] 
Glutamate, despite being the main excitatory mediator in the retina and though it 
permits the nerve signal transmission from the photoreceptors to bipolar cells and 
then to ganglion cells, can result damaging if present in excessive doses at the 
extracellular level: it in fact provokes the so-called excitotoxicity, i.e. a nerve 
damage caused by hyperexcitation. It is the result of the hyperactivation of post-
synaptic receptors NMDA (n-methyl-d-aspartate) which provoke the opening of 
the calcium channels on neuronal membranes; the consequent high intracellular 
levels of this ion trigger a signal cascade leading to caspase-3 or AIF-mediated 
cell death, and, stimulating the phospholipase, promote the release of cytotoxic 
fatty acids into neurons and the extracellular space. [159, 160] 
The excessive glutamate concentration in the retina is probably caused both by 
the insufficient glutamine synthetase activity and the reduction in GLAST 
transporters. [161] It would moreover seem that the high extracellular glutamate 
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levels induce the neuronal and glial swelling, with the consequent reduction of 
extracellular space and neuronal hyperexcitability. [157] 
A second fundamental function of Müller cells consists in the inactivation of the 
inhibitory neurotransmitter GABA (gamma-aminobutyric acid). After its release by 
the inhibitory interneurons, GABA is channeled into this type of glial cells and 
then deviated into the Krebs cycle through the degradation carried out by GABA-
transaminase. The Ishikawa group has detected an increase in GABA levels in 
diabetic rats’ Müller cells, caused either by the reduction of GABA-transaminase 
activity or, more probably, by the compromission of the citric acid cycle: such an 
increase would concur with the neuronal dysfunction. [162] 
 
1.7.5. The Renin-Angiotensin System (RAS) 
 
In the standard renin-angiotensin system (RAS), responsible on the systemic 
level for the control of blood pressure, salt absorption and aldosterone formation, 
the angiotensinogen is cleaved by the enzyme renin in order to form Ang I, which 
is activated by Ang II of the ACE enzyme. Ang II acts through two receptors 
AT1R and AT2R, the first of which seem to mediate most of the RAS functions. 
[163] 
 In the recent years, many studies have shown that alongside the systemic RAS, 
there are local RAS in different organs including the retina, where, besides 
exercising nerve and vascular functions, it contributes to the regulation of the 
aqueous humour pressure. Mice models have evidenced the presence of all RAS 
components in the retina and a higher Ang I and Ang II concentration in the 
anterior uvea, the retina, the retinal pigment epithelium and the choroid with 
respect to the plasma, confirming the presence of a local system. Since it has 
been observed that the most conspicuous RAS component is found on the level 
of capillaries, neurons, the inner retinal layers’ glia, it is generally thought that 
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these are the most probable sources of the local RAS. The presence of renin and 
angiotensin in the glia and in the neurons points at their involvement not only in 
neuromodulation, but also in angiogenesis, given their close relationship with the 
vessels.[111, 163, 164] 
 
 
Figure 16.  A section of mice retina marked with AT1R and AT2R antibodies. (A) AT1R is 
prevalently localizes in glial and bipolar cells, while (B) AT2R is expressed by amacrine 
cells. OPL: outer plexiform layer; INL: inner nuclear layer: IPL: inner plexiform layer; GCL: 
ganglion cell layer.[165]  
 
With respect to the receptors, Phipps et al. have recently analyzed the 
localizations of two receptor types, with the result that AT1R was detected in 
astrocytes, Müller cells, bipolar cells and endothelial cells, while AT2R was 
detected in amacrine cells. [163] The Downie group has subsequently recognized 
a different function for each of the two receptors: AT1R would appear to be 
implicated in the neovascularization of hypoxia-induced retinopathies, while the 
role of AP2R is much less clear, though it would appear to oppose or 
compensate AT1R functions, and above all, it could be implicated in the nerve 
tissue survival and reparation.[166] 
In the course of diabetic retinopathy, the Ang I, Ang II, renin and ACE levels 
result increased. Ang II provokes, through AT1R, the alteration of the hemato-
retinal barrier, stimulates the release of VEGF and PEDF, favours the leukocyte 
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adhesion, modulates the pericyte activity, the expression of tight junctions and 
the neovascularization. [165] Ozawa et al. have noticed that the Ang II 
hyperproduction leads to the hyperactivation of AT1R and subsequently of ERK 
(extracellular-signal-regulated kinase), which in turn induces a diminished 
expression of synaptophysin, a protein contained inside the synaptic vesicles and 
fundamentally important for the neurotransmitter release, through its degradation 
mediated by UPS (ubiquitin-proteasome system). They have moreover 
demonstrated that Ang II induces ROS production, which in turn stimulates the 
production of proinflammatory cytokines, the inhibition of BDNF and the activation 
of ERK, inducing cellular apoptosis. [167] 
 
Figure 17. Retinal neurodegeneration and visual function compromission mediated by 
Ang II. AT1R: angiotensin II type receptor, ROS: reactive oxygen species; BDNF: brain-
derived neurotrophic factor. [167] 
 
As already mentioned, the role of AT2R is less clear: a hypothesis claims that 
Ang II provokes the activation of GABAergic amacrine cells with consequent 
increase in GABA release and the subsequent inhibitory effect on the bipolar 
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cells in rods.[165] The hyperactivation of AT1R and AT2R would therefore have 
an overall inhibitory effect on neuronal transmission, which would lead to 
apoptosis.[31] 
 
1.7.6. Reactive Oxygen Species (ROS) 
Oxidative stress is another key factor of the neuroretinal damage during the 
course of diabetes mellitus: it has been, in fact, observed in diabetic mice that the 
administration of lutein, an antioxidant able to reduce local ROS, allows for the 
normalization of the electroretinography (ERG) and the levels of synaptophysin, 
as well as for the prevention of neuronal prevention.  
The ROS cause the NO reduction in diabetic subject’s retina, a consequent 
increase in peroxynitrite and the subsequent reduction of the NGF and BDNF, 
responsible for the reduced neuronal growth and apoptosis, as well as the 
compromission of synaptic activity.  
The oxidative stress also provokes the damage of Müller cells, through the down-
regulation of Kir4.1 and AQP4 channels and the reduction of MMP-7 (matrix 
metalloproteinase-7) which converts the pro-NGF, toxic for the neurons, into the 
neuroprotector NGF. [167] 
 
1.7.7. Advanced Glycation End-products (AGEs) 
AGEs (advanced glycation end products) and ALEs (advanced lipoxidation end-
products) concur at the onset of retinal damage during the course of diabetes 
mellitus. While it is generally acknowledged that the AGEs contribute to the 
dysfunction of the hemato-retinal barrier, to the thickening of the capillary 
basement membrane and to microvascular degeneration, the contribution of 
ALEs is less clear, although it is known that both of them accumulate especially 
inside Müller cells and that they are connected to the ROS generation and the 
activation of proinflammatory and proapoptotic pathways. [97] 
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RAGE (AGEs receptor) is expressed in an ubiquitous way in almost all retinal 
cells, but it would appear to be more represented in the glial cells of the inner 
retinal layers, and especially in Müller cells.[92, 168] 
The chronic retinal exposition to hyperglycemia determines the hyperproduction 
of the AGEs and ALEs and Curtis et al. have observed that the inhibition of the 
latter protects against the Kir4.1 and AQP4 malfunctioning, suggesting that the 
dysfunction of Müller cells might be connected to their intracellular 
accumulation.[97] 
Different studies have demonstrated that RAGE hyperexpression reaches its 
maximum levels in Müller cells during the diabetic pathology. The RAGE 
activation by the ligands such as AGEs and S100B, a calcium-tying protein, leads 
to the alteration of many retinal cells, including Müller cells and the microglia. 
This entails an inflammatory and oxidative response which induces, as well as 
the well-known microvascular dysfunction, also the neurodegeneration of the 
retina mediated by the secretion of growth factors and cytokines, the 
strengthening of pro-oxidative and inflammatory factors, the alteration of the 
extracellular matrix, the activation of Müller cells and the microglia, and cellular 
apoptosis.[97, 168] 
Zong et al. have furthermore demonstrated that S100B, produced mainly by 
Müller cells and astrocytes, is significantly increased in hyperglycemic conditions. 
GFAP, S100B and RAGE, have resulted significantly incremented during 
diabetes in Müller cells, a fact probably connected to gliosis. This group has 
therefore shown that the RAGE hyperexpression induced by hyperglycemia 
carries out an important role in the activation of Müller cells and the subsequent 
cytokine production in the context of diabetic retinopathy.[92, 168]  
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Figure 18. Increased S100B, RAGE and GFAP expression in a diabetic mouse. The 
three molecules are evidenced by fluorescent antibodies: S100B in red (a and b), RAGE 
in green (a), GFAP in green (b). MERGE: union of the two precedent images; ILM: inner 
limiting membrane; IPL: inner plexiform layer; INL: inner nuclear layer; ONL: outer nuclear 
layer; ELM: external limiting membrane.[92] 
 
1.7.8. Neuroprotective Factors 
The balance between neurotoxic and neuroprotective factors is crucial for the 
determination of retinal neurodegeneration in the diabetic patient. Among 
different neuroprotective factors produced by the glial cells, one must remember 
PEDF (pigment epithelium-derived factor), VEGF and the neurotrophins.  
VEGF, which promotes the neovascularization and the increase in vascular 
permeability, is expressed by endothelial cells, neurons and glial cells, especially 
Müller cells, and its effect is contrasted by PEDF and thrombospondin-1. VEGF 
moreover regulates the survival and the proliferation of neurons and glial cells, 
having a potent anti-apoptotic and neuroprotective effect. Such effect is lacking 
during diabetic pathologies probably because, despite a significant increase in 
VEGF, the high peroxynitrite levels block the anti-apoptotic pathway by inhibiting 
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survival proteins and stimulating the pro-apoptotic pathway. [21, 157] The 
deletion of VEGF gene in glial cells furthermore reveals the importance of their 
communication with vascular cells in the angiogenetic process. [11] This 
molecule, along with other pro-angiogenetic cytokines and high glutamate levels, 
increases the release of matrix metalloproteinase by the endothelial cells and 
Müller cells: this, on one part, damages the tight junctions of the endothelium and 
of the RPE by means of the proteolytic occludin degradation, and, on the other, 
entails the loss of contact inhibition which usually prevents endothelial 
proliferation. [100] 
PEDF results reduced during diabetic pathology probably because the hypoxia 
and VEGF increase the matrix metalloproteinase activity which in turn degrades 
the PEDF. Expressed by retinal neurons, glial cells (Müller cells in particular), 
vascular endothelium and EPR, it constitutes one of the most important 
angiogenesis inhibitors and it protects the neurons from the neurodegeneration 
caused by glutamate. [21, 157] 
Among the neurotrophines, molecules involved in the neuroretinal development 
and the nerve cell regeneration, the most important ones to remember are BDNF, 
NGF, GDNF and CNTF.[160] The neurotrophins possess high affinity for tyrasine 
kinase receptors (Trks), which mediate cell survival and growth, while they have 
a low affinity for the neurotrophic receptor P75 (p75NTR), member of the TNF 
(tumor necrosis factor) family, which regulates apoptosis and reduced cellular 
growth. [169] 
NGF is secreted and synthesized by glial cells, and Müller cells in particular, 
starting with proNGF, which is proteolytically cleaved by the enzyme furine on the 
intracellular level and by MMP7 on the extracellular level. While NGF promotes 
the survival of neuronal cells through the link with TrkA and p75NTR receptors, 
proNGF induces their apoptosis due to its greater affinity towards p75NTR. 
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The inflammation and the oxidative stress observed during the course of diabetes 
induce a ROD increase in the neuroretina which leads to a reduced NO 
biodisponibility, despite its increased production, and to the formation of 
peroxynitrite. High peroxynitrite levels cause the pro-NGF hyperproduction on the 
part of activated Müller cells and they prevent its maturation into NGF through 
MMP-7 inhibition: this leads to pro-NGF accumulation and NGF reduction with 
consequent death of neuronal and endothelial cells and as well as the 
compromission of the hemato-retinal barrier. The neurodegeneration is promoted 
also by receptor alterations: although TrkA expression remains unchanged, its 
activity is compromised, while the hyperexpression of p75NTR causes the 
prevalence of apoptosis. [169-171] The increase of pro-NGF in the intraocular 
tissue would hence signify an attempt by the cells to stimulate the inhibited 
pathway, even though it results inefficient due to the alteration of receptor 
pathways. [170] 
BDNF is expressed in many retinal cells, including Müller cells and neuronal 
cells, and is fundamental for the survival of ganglion and amacrine cells and for 
the synaptic functionality, since BDNF protects the neurons from cellular death 
via the tyrosine-kinase receptor TrkB. [172] BDNF levels are regulated also by 
the neuronal synaptic activity, suggesting that their maintenance might involve 
the preservation of synaptophysin. It has been stated that in the diabetic subject’s 
retina the BDNF levels result reduced both in ganglion cells and in the Müller 
cells. [173] 
GDNF is usually expressed by photoreceptors, to a lesser extent when compared 
to the Müller cells and the astrocytes. It induces a FGF increment in Müller cells, 
and favours photoreceptor survival, protecting the ganglion cells from glutamate-
mediated apoptosis through the increased uptake of the latter by GLAST. Zhu et 
al. have recently demonstrated that in hyperglycemic conditions there is an 
hyperexpression of GDNF and its receptors GFRα1 and GFRα2 on the part of 
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Müller cells, suggesting that it might be a protective reaction directed toward the 
nerve and glial cells. [98, 174] 
Less known is the role of CNTF, which promotes the survival of photoreceptors 
and ganglion cells. The levels of such molecule, produced by the Müller cells, the 
asctrocytes and the RPE, increase the rate of retinal degeneration, which is quite 
possibly also what happens in diabetic pathology.[98]  
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1.8. Spectral Domain OCT (SD-OCT) 
 
Figure 19. Photo of SD-OCT HRA+OCT (Heidelberg Engineering, Heidelberg, Germany).  
 
1.8.1. Comparison between Time Domain OCT (TD-OCT) and Spectral 
Domain OCT (SD-OCT) 
The optical coherence tomography (OCT) is a non invasive technique which 
provides high resolution images of cross-sections of the retina in vivo. Compared 
to CAT scans and ophtalmoscopy, it has a greater spatial resolution, an inferior 
acquisition time, and it does not need direct contact with the ocular surface. [175]  
Its use allows to obtain more precise distinctions of retinal layers compared with 
the histological method, thanks to the system’s high definition. [20] 
The OCT is based on the ‘low coherence interferometry’ technology, initially 
applied in ophthalmology for the in vivo measurement of the ocular axial length. 
The procedure is analogous to the CAT scan, but, because it uses light waves in 
place of sound waves, it allows to measure the intensity and the delay time of the 
light reflected echo pulses. [20] 
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The oldest type of Time Domain OCT (TD-OCT) emits, via a superluminescence 
diode, a low-coherence light beam directed towards the retina with the 
wavelength similar to the infrared (843 nm) one. This beam crosses a partially-
reflecting mirror which splits it in two beams: the reference beam and the sample 
one. While the sample beam is directed towards the analyzed eye and is 
reflected by the ocular tissues according to their distance and their characteristics 
of density and thickness, the reference beam is reflected by a longitudinally 
oscillating mirror. Both beams return to the partially-reflecting mirror around the 
same time, recombine in the interferometer are transmitted to photosensitive 
detector. The constructive interference between the light impulses reflected by 
retinal structures and the reference mirror happens only if these impulses reach 
the interferometer at the same time and only then it is possible to detect the 
resulting signal and intensity.  
The interferometer, therefore, detects, elaborates and memorizes the delay 
schemes of the echoes coming from the retina and this operation is repeated in 
the whole duration of the scan. The obtained bidimensional image (tomogram) 
represents a cross-section of the tissue analyzed by the light beam, and the 
difference, in terms of the frequencies absorbed by the tissues, is translated into 
a number to which a colour or a shade of grey is assigned according to the 
difference in reflectivity of the layers at different depths: the highly reflective 
structures are visualized in brilliant colours like white or red (nerve fiber layer and 
RPE), the low reflective structures are represented with darker colours like black 
or blue (photoreceptor layer and the inner and the outer nuclear layers), while the 
moderately reflecting structures appear grey-white or green (inner and outer 
plexiform layers). The intensity of the signal depends on the optical properties if 
the examined tissues’ structures and on different preretinal factors, e.g. media 
opacity. [20, 175-178] 
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The newer Spectral Domain OCT (SD-OCT), or Fourier Domain OCT, uses 
instead a fixed reference mirror and a spectrometer which catches the incident 
signals. The information provided by the spectrometer is converted into the depth 
scans of the Fourier-transform, an operation which consists in a series of 
formulas able to break down any wave into the sum of harmonics that compose 
it. Measuring thus all the light echoes simultaneously, and not sequentially as it 
occurs for the TD-OCT, the SD-OCT increases significantly the quantity of data 
acquired with each scan, with an important reduction in movement artifacts, an 
increase of signal-ground noise ratio, a greater image resolution, a more precise 
definition of retinal layers, a greater acquisition speed and a possibility to 
precisely map the optic nerve head. 
By using the appropriate software, SD-OCT can moreover elaborate 3D images 
and compare them to the photographic, angiographic and autofluorescence 
images. [175, 179, 180] 
Comparing the two OCT types, many differences can be detected which explain 
the SD-OCT advantages. The TD-OCT realizes 400 A-scans (monodimensional 
scans) per second, and the B-scan (bidimensional) images have an axial 
resolution of 10 μm. This definition, however, can lead to failed diagnoses of the 
milder retinal alterations and it is not likely that it can distinguish the RPE-Bruch’s 
membrane complex, which causes the exclusion of the retinal thickness from the 
measuring process, with subsequent underestimation of the same. The SD-OCT, 
however, has a greater repeatability of measurement compared to TD-OCT, even 
though its different models, using its own calculation algorithms, result in different 
values for retinal thickness, so that the two are not interchangeable.[184] 
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Figure 20. OCT images of the same non-pathologic macula made by (a) first generation 
TD-OCT (Stratus OCT), (b) second generation TD-OCT (Cirrus HD-OCT) and (c) SD-
OCT (Spectralis HRA+OCT). Note the progressive improvement in image definition. [185] 
 
In order that the OCT may be used for the qualitative evaluation of the structural 
retinal pathologies caused by other ocular pathologies, e.g. diabetic retinopathy, 
it is necessary to carry out a segmentation of different retinal layers, which 
permits the individuation and the evaluation of thicknesses. There are, however, 
two problems regarding the automatic segmentation: the first one consists in the 
fact that the pathologic retina usually presents substantial alterations which can 
affect the results of the procedure, and the second one consists in the fact that 
the transparency loss of the dioptric media creates an unclear image with spotted 
areas which hamper with the procedure.  For these reasons, there is usually the 
need for an operator to manually correct the automatic segmentation, thus 
correcting  the errors caused by accumulations of liquids in the retina. [186, 187] 
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1.8.2. The importance of OCT during the course of diabetic pathology 
By now, it has been generally acknowledged that the OCT constitutes a valid 
instrument for the diagnosis of diabetic macular edema. Forooghian et al. have 
demonstrated that measurements of macular thickness and volume when carried 
out by SD-OCT result significantly more precise compared those measured by 
TD-OCT. [185, 188] Beside the central retinal thickening, in the case of macular 
edema, the OCT can also show the intraretinal cysts, subretinal fluids and signs 
of vitreofoveal traction. [175] 
A number of studies have evidenced that the OCT is able to detect the retinal 
thickness’ anomalies already in diabetic patients with no signs of retinopathy and 
in those with mild, moderate or severe retinopathy without clinically significant 
edemas, reporting, however, contrasting results. Most of these studies have used 
TD-OCT.  
Schaudig et al. have described an increased macular thickness of the superior 
quadrant in diabetic subjects with DR compared to those without DR and to 
healthy controls. [189]  The Pires and the Sànchez-Tocino groups have also 
detected a thickening in certain macular areas in the early stages of DR. [190, 
191] Conforming to this data, Oshitari et al. have noticed an increase in macular 
thickness and a reduction in RNFL thickness in patients with initial stages of 
diabetic retinopathy, suggesting that they might be caused by neuronal 
degeneration and the increase of vascular permeability. [192] The Lattanzio 
group has moreover evidenced a macular thickening in diabetic patients without 
retinopathy when compared to healthy controls. [193] Sng et al. have instead 
detected an increase in the foveal and the external temporal macular area 
thickness in patients with moderate or severe retinopathy without DME, while 
there was no significant difference between diabetic patients with mild and 
normal retinopathy. [194] 
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By contrast, the Massin, Alkuraya and Bressler group have not reported 
significant differences in macular thickness in patients without or with mild 
retinopathy with respect to healthy controls. [195-197] 
On the other hand, in two independent studies, the Biallosterski and the Nilsson 
groups have noticed a significant reduction in macular thickness in diabetic 
patients with mild retinopathy, suggesting that it may be caused by the loss of 
nerve tissue. [198, 199] Asefzadeh et al. have observed that macular thickness is 
significantly inferior in subjects without or with mild retinopathy compared to 
subjects which present one of the more advanced forms of this condition.[200] 
Lastly, the Verma group has noticed a reduction of the macular thickness in 
diabetic patients without retinopathy and a proportional reduction of retinal 
sensitivity, detected via microperimetry. [181]   
Such differences in the measurements of total macular thickness may be 
explained in various ways: for example, certain works have completely excluded 
subjects with macular edema, while others have not; some have considered 
exclusively subjects affected by type 1 diabetes, others only the type 2 diabetic 
subjects, while certain works have considered both types; usually the used 
instruments were different; and, lastly, in many cases, the studied population was 
not divided according to the characteristics which affect the measurements, such 
as age, gender, ethnicity and myopia.  
Van Dijk et al. have recently noticed, this time using the SD-OCT on patients with 
mild retinopathy and afflicted by type 1 diabetes mellitus, a thinning of GCL in 
pericentral macular area and in RNFL in more peripheral macula. GCL is afflicted 
in an earlier stage, and is compromised in direct proportion to the duration of 
diabetes, while RNFL is afflicted only subsequently, since the axonal 
degeneration follows the cellular body degeneration. [201, 202] Contemporarily, 
Cabrera et al. have observed that the RNFL and the GCL+IPL appear thinner in 
diabetic subjects with or without mild diabetic retinopathy, resulting therefore 
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more susceptible to the initial damage. [184] The Peng group has also detected 
the RNFL thinning in the superior quadrant of diabetic patients without 
retinopathy. [203] Finally, a recent study by Araszkiewicz et al. has evidenced a 
reduced thickness of RNFL, GCL and of the total macula in diabetic patients with 
RD and without DME, compared to patients without RD. [204] In accordance with 
these results, two studies which have used SLP (scanning laser polarimetry) 
have pointed at RNFL thinning especially in superior quadrants of diabetic 
patients. [205, 206]  
Lastly, two recent works presented at the ARVO (Association for Research in 
Vision and Ophthalmology), which have used the most recent SD-OCT 
technology, have evidenced certain morphological alterations in vivo on the retina 
of diabetic subjects: in the first study, a significant increase of ILM, IPL, INL 
thicknesses has been observed as well as a decrease of GCL and RNFL 
thickness in patients with non proliferative retinopathy, while the second one has 
detected a thickening of the INL+IPL complex and the presence of 
microaggregates in ILM and RNFL, which indicate an activated microglia.[207, 
208] 
Considering the concepts explored so far, it can be understood how in diabetic 
patients the OCT has shown itself to be a very useful instrument not only 
regarding the patients with diabetic retinopathy but also regarding the ones who 
do not present such complication, demonstrating the ways in which neuronal 
damages precede the vascular damage.  
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PURPOSE OF THE STUDY 
The objective of this study is to investigate the eventual differences, both 
qualitative and quantitative, in the expression of specific proteins inside the 
aqueous humour sampled both in healthy subjects and in diabetic patients with or 
without retinopathy. The purpose is to identify the possible biomarkers of glial 
activation, implicated in the degenerative neovascular process and to put them in 
relation with the stage of the retinal compromission. We have chosen to analyze 
the aqueous humour because the collection of samples results less invasive 
compared to the analyses of the vitreous (the object of study of most published 
papers), while the information provided by its analysis is equally useful for the 
understanding of the onset and progression of diabetic retinopathy.  
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MATERIALS AND METHODS 
3.1. Bibliographic research 
As regards the selection of molecules to investigate, a bibliographic research has 
been conducted on PubMed, with no year limit, inserting and associating in 
different ways the key words: “diabetic retinopathy, diabetes, neurodegeneration, 
retinal degeneration, neural apoptosis, neuroprotection, physiopathology, 
ganglion cell, glia, Müller cell, astrocyte, microglia, glial activation, inflammation, 
aqueous humor, vitreous, tear fluid, ELISA, protein array, protein, proteomics, 
aquaporin, GFAP, cytokine, neurotrophins, renin angiotensin system, reactive 
oxygen species, glutamate, advanced glycation end products, oxidative stress, 
biomarkers”. 
A list of proteins has therefore been defined as the object of study of the aqueous 
humour, based on which a more elaborate study has been conducted.  
 
3.2. Study Population 
34 eyes of the same number of patients of legal age have been studied at the 
Eye Clinic of the University of Padua, from January till July 2012.  
The study population has been selected in such a way that it forms four groups:  
 Control group: 12 subject not affected by diabetes mellitus 
 Study group: 22 subjects affected by type 1 or 2 diabetes mellitus. This 
group has been further divided in three subgroups according to the 
presence of non proliferative diabetic retinopathy (NPDR) and macular 
edema (ME): 
 11 diabetic patients without clinical signs of NPDR. 
 11 diabetic patients with clinical signs of NPDR of which 5 without 
ME and 6 with ME. 
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In every subject the cataract diagnosis was present, with indications for the 
phacoemulsification and the intraocular lens implantation intervention. An 
informed consent was obtained from each patient and the research has been 
carried out in accordance with the Declaration of Helsinki regarding the 
experimentation involving human tissue, and has been approved by the Local 
Ethics Committee.  
The diagnostic criteria used for the inclusion of patients in the group of diabetics, 
valid for both sexes and for every age, have been established in 2011 by the 
WHO (World Health Organization): glycated hemoglobin>6.5% in two occasions, 
or glycemia ≥126 mg/dl after at least 8 of fasting in two occasions, or glycemia 
≥200 mg/dl after 2 hours from a oral glucose tolerance test to be confirmed by a 
fasting test, or casual glicemia ≥ 200 mg/dl in presence of typical symptoms 
(polyuria, polydipsia, weight loss). [209] 
The study has not taken into consideration patients affected by 
neurodegenerative disease (e.g. Alzheimer’s, Parkinson’s, dementia), neoplasia 
in the central nervous system or other nerve pathologies which affect sight and 
unrelated to diabetes; subjects who systematically took steroid treatments and/or 
anti-VEGF therapies and/or medicines treating the central nervous system or with 
neuroprotective effects in the three months preceding the intervention; patients 
afflicted by poorly controlled systemic pathologies. In addition, the study has 
excluded patients whose studied eye presented: intraocular pressure greater or 
equal to 22 mmHg or with a history of glaucoma; other ocular pathologies of 
vascular, degenerative or inflammatory nature not ascribable to diabetes; topical 
therapies with ocular antihypertensive drugs, cortisone drugs, FANS or anti-
VEGF drugs in the 30 days before intervention; eye surgery history in the three 
months before intervention; subjects who, in ophtalmoscopy or OCT exams, 
presented significant vitreo-retinal tractions which could affect retinal thickness; 
excessive opacity of the dioptric media which prevented ophtalmoscopic 
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evaluation or the acquisition of retinal images with OCT which could prevent a  
certain evaluation of presence/absence  of DR or other retinal pathologies. Lastly, 
subjects who had participated in other clinical studies in the 90 days before 
intervention have been also excluded. 
After collecting a clinical and pharmacological anamnesis, ocular and general, 
every patient has underwent a complete eye exam in accordance with the routine 
clinical preoperative procedure, which consisted in the evaluation of visual acuity 
and refraction, slit-lamp biomicroscopy, tonometry, and the ophtalmoscopic exam 
of the eye fundus with eventual grading of DR according to internationally 
established criteria. [28] Each subject has moreover undergone an OCT exam of 
the studied eye.  
 
3.3. OCT Exam 
Every subject’s studied eye has undergone the spectral domain optical 
coherence tomography (SD-OCT) with Spectralis HRA+OCT(Heidelberg 
Engineering, Heidelberg, Germany). Two scan patterns have been used:  
  “7 Line Raster Scan”: 6mm linear scans centered at the fovea at 0°, 30°, 
60°, 90°, 120°, 150° in ART mode (100 images averaged). 
 “Dense Volume Scan”: macular area of 6x6 mm centered at the fovea 
(512x456 pixel) in ART-mode (60 images averaged). 
For each SD-OCT linear scan, an automatic algorithm has individuated different 
retinal layers based on the different shades of gray corresponding to the 
reflectivity indexes of each layer. 
The available algorithm (version 5.5.0.5) was, however, able to elaborate this 
stratification in a reliable way only on the linear scans of the fovea, not on those 
of the macular mapping. For this reason, various linear scans have been 
extrapolated from the “7 Line Raster Scan” acquisition, and have undergone the 
automatic stratification with a consequent correction by an operator. Since the 
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error of the instrument consisted in the inexact identification of the border lines 
between retinal layers, the manual correction consisted in the repositioning into 
proper place of the incorrectly placed points, in order to redefine the retinal 
profile.  
 
 
Figure 21. Visualization screen at the SD-OCT exam with Spectralis HRA+OCT. On top 
left there is an infrared image of the eye fundus with the localization and the direction of 
the scanning; on top right, the scan image with the identification of RNFL (between the 
two dividing lines); on bottom left, the middle value of the considered layer in different 
distance intervals from the fovea; on bottom right, the graph representing the thicknesses 
of the considered layer in different intervals.  
 
For each of the 6 scans, 6 retinal layers of interest have been segmented, which, 
from inside to out, were: 
 Retinal nerve fiber layer (RNFL): from the inner limiting membrane (ILM) 
to the border with the ganglion cell layer;  
 Ganglion cell layer (GCL): from the border with the nerve fiber layer to the 
border with the inner plexiform layer; 
 Inner plexiform layer (IPL): from the border with the ganglion cell layer to 
the border with the inner nuclear layer;  
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 Inner nuclear layer (INL): from the border with the inner plexiform layer to 
the border with the outer plexiform layer; 
 Outer plexiform layer (OPL): from the border with the inner nuclear layer 
to the border with the outer nuclear layer; 
 Outer nuclear layer (ONL): from the border with the outer plexiform layer 
to the border with the external limiting membrane (ELM). 
 
For each layer of each linear scan (at 0°, 30°, 60°, 90°, 120°, 150°), the algorithm 
has automatically calculated the average thickness of 0.5mm side intervals 
starting from the fovea, the so-called ‘point 0’, up to 2.5 mm away from it (for the 
total length of 5mm). In this way, 5 intervals have been defined on each side (10 
in total) starting from the point 0, which were: -2.5/-2mm, -2/-1.5mm, -1.5/-1mm, -
1/-0.5mm, -0.5/0mm, 0/+0.5mm, +0.5/+1mm, +1/+1.5mm, +1.5/+2mm, 
+2/+2.5mm (the negative and positive values have been attributed based on the 
orientation with respect to the fovea). Each interval of each scan has been 
identified by the arbitrarily assigned progressive numbering (from 1 to 60), 
resulting in a diagram which has helped create a map of analyzed points (figure 
22). 
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Figure 22. Representation of the intervals considered (60 in total) in the analyzed scans. 
Spatial positioning with respect to the fovea: S: superior; N: nasal; I: inferior; T: temporal. 
 
The intervals have been compared in various patients considering the right eye 
as reference, while the relative points of the left eye have been analyzed 
according to the way in which the comparison of the areas in ETDRS chart 
functions. 
 
3.4. Collection, conservation and analysis of aqueous 
humour 
All patients have undergone the normal preoperative preparations for the 
phacoemulsification surgery and the intraocular lens insertion: disinfection of 
periocular skin with povidone-iodine 5%, instillation of sterile lidocaine, irrigation 
of the conjunctival sac with povidone-iodine 5% and abundant washing out of the 
eye with BSS (balanced salt solution). 
A quantity of aqueous humor (between 150 and 200 μl) has been aspirated from 
the anterior chamber of the eye, carrying out a parecentesis under microscope 
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with a 30 gauge needle and an insulin syringe (1 ml), and avoiding all contact 
with the intraocular tissues, since they are possible sources of sample 
contamination. 
Immediately after the aspiration of AH, the first operator has carried out the 
subsequent surgical maneuvers according to normal surgery procedure, while a 
second operator has handled the division and the conservation of material. 
The collected sample has been divided into two 50μl aliquots which were placed 
into conical test tubes of 1.7ml each, previously numbered in a progressive way 
and conserved at temperature of +4°C. 
Each of these contained 50μl of RIPA buffer (RadioImmunoPrecipitation Assay 
buffer) which was modified (25mM Tris-buffer, 150mM NaCl, 0.1% Tween20, 
1mM EDTA -EthyleneDiamineTetraacetic Acid-, 10% glycerol, 0.1% SDS -
Sodium Dodecyl Sulfate-, 10mM NaF e 1mM PMSF -Phenylmethanesulfonyl 
Fluoride-; ph=7.5) and to which 50µL T-PER (Protein Extraction Reagent) 
supplemented with a cocktail of protease inhibitors (code #0078510; Pierce 
Biotechnology, Rockford, IL) was added. The excess material was placed into a 
third empty test tube.  
After closing and delicately shaking the test tubes in order to favor the complete 
mixing of the sample with the conservation medium, on each test tube only and 
exclusively the reference “PT: ID code” (Patient: identification code of the study 
subject) was added.  
Within an hour from the collection, the samples were transported in portable 
thermal containers from the OR to the refrigeration cell where they were frozen at 
-20°C and conserved.  
After having collected all the samples, they were shipped to the IRCCS (Institute 
for Recovery and Care of Scientific Characteristics), G.B. Bietti Foundation for 
Study and Research in Ophthalmology (Rome), in accordance with the 
international regulations regarding the transport of biological material.  
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In the laboratory unit, the samples were conserved at the temperature of -70°C. 
After the quality/quantity analyses of total protein, and before the subsequent 
protein analyses (ELISA and protein array), the AH has been treated sonically 
(VibraCell, Sonics, Newton, CT) in order to effectively extract cell protein (to 
share DNA/RNA), and then clarified by centrifugation.  
 
3.4.1. Quantitative determination of total protein 
 
According to the study design, the sampling of AH was carried out dividing the 
total collected amount in two different buffers (T-PER and RIPA) which allow 
specific analysis.  
For RIPA sampling, the quantification of total protein was carried out according to 
the Bradford method. In brief, 2μl of AH were diluted with 18μl of ddw (water 
DirectQ5; millipore.com) and mixed with 200μl of a prediluted solution (code 500-
0006; Biorad, bio-rad.com). After a brief incubation of 5 minutes at room 
temperature, 3μl of each sample and of a reference standard curve (0-1000μg/ml 
BSA; sigma-aldrich.com) were acquired at the digital spectrophotometer with the 
appropriate Bradford option (Nanodrop ND1000 UV-Vis Spettrofotometer; 
nanodrop.com). The protein concentration was calculated based on the 
linearized standard curve (BSA) as provided by the program.  
For T-PER sampling, 3µL samples were directly evaluated by digital 
spectrophotometer, using the A280 option with comparison to a standard (IgG), 
as provided by the manufacturers. Both evaluations were carried out after blank 
options, both against ddw and appropriate buffer. The data was used to evaluate 
possible variations in total protein content between groups and to normalize the 
samples before loading in the specific assay.  
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This analysis allowed the evaluation of the potential variations in total protein 
concentrations between and within different groups, and the normalization of the 
samples before proteomic analyses.  
 
 
Figure 23. Protein quantification with Bradford method: from left to right we notice the 
increasing protein concentrations. 
 
3.4.2. GFAP, AQP1 and AQP4 Analyses with ELISA test 
 
The ELISA tests used to quantify GFAP, AQP4 and AQP1 were the following: 
GFAP-NS830 (millipore.com), AQP1-MBS700396 (mybiosource.com), AQP4-
MBS705290 (mybiosource.com). 
This double-sandwich ELISA is a solid phase assay which uses 96well-plastic 
pre-coated plates, which permits to contemporarily assay a high number of 
samples (up to 40 samples in duplicate) from different patients in order to analyze 
the same molecule. As in the protocol provided by the manufacturer, for every 
specific ELISA, both prediluted samples and standard curve, prepared in TBS 
buffer (20mM Tris-Cl and 150mM NaCl, containing 3% of BSA, 5mM EDTA and 
1x protease inhibitor cocktail) were applied to the pre-coated plates appropriately 
pre-absorbed. Standard curves (range) and limit detections were as follows: 
GFAP, 1.5-100ng/mL and 1.5ng/mL; AQP4, 15.6-1000pg/mL and less than 
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6.6pg/mL; AQP1, 15.6-1000pg/mL and less than 3.9pg/mL. After an incubation 
period of 18hrs and the appropriate washes, the appropriate biotin-conjugated- 
antibodies and the streptavidin-peroxidase complex were added, as provided by 
the kit. The specific binding was visualized by adding the TMB 
(tetramethylbenzidine) substrate (ebiosource.com). In case of the presence of the 
antibody-biotin-streptavidin-peroxidase complex, the sublayer turns to yellow with 
the intensity proportional to the antigen concentration in the sample. The enzyme 
reaction was blocked through acidification (adding the 2N HCl stop solution) and 
the colorimetric signal was read by the Sunrise plate reader spectrophotometer of 
(tecan.com) at 490nm wavelength. Finally, the GFAP, AQP1 and AQP4 
concentrations in the samples were estimated according to the 3rd grade 
polynomial standard curve provided by the manufacturer.  
 
 
Figure 24. ELISA kit used for  AQP1 and AQP4 quantification 
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3.4.3. Inflammatory profile analysis with protein-array  
 
The protein array was conducted using the RayBiotech technology established by 
the manufacturer (raybiotech.com). This method offers the advantage of 
contemporary evaluation, for every single sample, of a significant number of 
proteins, depending on the precostumized array. Both membrane (array series 
with 4 pre-spotted membranes) and glasschips (G series comprising 1 slide with 
4 or 8 identical subarrays) were used in this study. Normalizations, 
Positive/Negative and Internal controls were carried out according to the 
procedure.  
Membrane-based arrays: All the samples were analyzed using the inflammatory 
array kit (#AAH-INF-3), providing all reagents suitable for analysis. As 
established by the manufacturer, the membranes were equilibrated in buffer 
solution and incubated with 300ng/ml of protein extract appropriately diluted in 
lysis buffer containing the protease-inhibiting cocktail. After an 18-hour incubation 
and the appropriate washes, the antigen-antibody binding was recognized by 
adding a cocktail of specific secondary biotin-conjugated antibodies, followed by 
the incubation with streptavidin conjugated to peroxidase. After further washes 
and the addition of the luminal substrate (ECL; SuperSignal West Pico Trial; 
pierce.com), the specific signals were acquired by Kodak Image working station 
equipped with the 1D Kodak Image Analysis software (Kodak 550, Eastman 
Kodak Company, Sci. Imaging Systems, Rochster, NY). The chemiluminescent 
signals (spots) were quantified using the single spot densitometry mode provided 
by the NIH 1D ImageJ software (Image J v1.43; http://rsb.info.nih.gov/ij/). The 
data was normalized according to the suggestion provided by the manufacturer 
and have subsequently been statistically confronted.  
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Figure 25. Membrane based protein array related to the inflammatory pathway.  
A. Schematic representation of the array. B. Representative chip-arrays specific for (from 
left to right: control, Diabetic w/o RP and Diabetic with RP). A dot represents a specific 
protein, as schematized in the map. The black intensity (ECL staining) represents the 
positive staining, as detected and quantified by Kodak. White color represent an over 
expression.  
 
Glasschip-based arrays. For the single staining, array-chips (#AAH-INF-G-3) 
were incubated with samples and the specific binging was labeled with a biotin-
conjugated cocktail of Abs, followed by a cy3-conjugated streptAvidin complex, 
and directly acquired by the Genepix 4100 microarray scanner (Molecular 
Devices LLC, Sunnyvale, CA) equipped with the GenePix Pro 3.0 software (Axon 
Instruments, Foster City, CA), according to the manufacturer’s procedure. The 
fluorescence signals were provided as median values, according to internal 
parameters. 
An extension of the chip-technology was developed to evaluate simultaneously 
differences in samples from 11 patients with diabetic retinopathy (with or without 
edema) as single staining (cy3 labeling), compared to a mix of samples from 11 
Inflammation profile
(protein array on membrane)
Control
(pt.7/vial14)
Diabetes
(pt. 13/vial 26)
Diabetes with RD
(pt. 10/vial 20)
A
B
C
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diabetic patients without diabetic retinopathy or 12 controls. In this double 
staining procedure, pathological and control groups were labeled with Cy3-dye 
and labeled proteins were purified in spin columns (GE Healthcare, 
gelifesciences.com). In parallel, a common reference protein was made from 
pooled samples from a selected group of individuals: total proteins were labeled 
with cy5 as previously reported. Each cy3-pathological/control sample was 
combined with an equal amount of pooled cy5-labeled common reference. A 1:1 
mix pathological: control mix (70µL/well/chip) was hybridized for 18hrs at 4°C. 
After washes in stringency conditions, the glass-slides were removed from plastic 
tray-support and washed once in ddw to remove salts and quickly spin to dry the 
chips. The double-fluorescence signals were acquired with the Genepix 4100 
microarray scanner. The software provides the cy3-signal for each spot to be 
compared with those of cy5-signal, represented by the common reference 
hybridized to the same chip/spot and expressed as ratio.  
 
 
 
Figure 26. Kit for cytokine quantification with protein array.  
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Array data analysis. Both chemiluminescence and fluorescence signals were 
analyzed and compared by NIH and StatView softwares. Normalization was 
carried out according to the instructions provided by the manufacturer. In the 
array approach, all comet tails were ignored and only median signal values were 
used for the identification of any biomarker variation. Particularly, the Internal 
Control (spiking-in proteins with no cross-reactivity with the samples) allows to 
normalize and compare signal intensities from array membranes and chips in 
different experiments/times. Only median signal values obtained after the 
acquisition with the same PMT settings, were used for the comparative analysis. 
Inter- and intra-assay CV≤10% was considered in the study and any ≥1.5-fold 
increase or ≤0.65 fold decrease in signal intensity, was considered to guarantee 
specific signals above background. A significance level of .05 was selected to 
limit the number of false-negative results. 
To acquire the spot signals, hand-made circle was drawn around the spot of the 
membrane-array image (35-bit tiff image), permitting the software to quantify the 
chemioluminescent signal and express it as optical density (OD). Data is 
provided as pathologic OD/control OD ratio. In the chip-array, the genepix 
software directly circles and evaluates the fluorescence signal inside each spot 
and provides a ratio value (MF) as pathological/ referring signal),which served for 
the normalization calculations. This approach would imply that the chip-based 
array is more precise than the membrane-based array. In order to minimize the 
intra- and the inter-assay variability, only the chip-based array data was used for 
the final statistical evaluation. The single tester handled all the material and 
followed all the phases of the experiment. 
The clusters of antibodies used for both arrays are as follows: eotaxin, eotaxin-2, 
G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte-
macrophage colony-stimulating factor), ICAM-1 (intercellular adhesion molecule-
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1), IFN-γ (interferon-γ), I-309 (chemokine (C-C motif) ligand 1), IL-1α (interleukin-
1α), IL-1β (interleukin-1β), IL-2 (interleukin-2), IL-3 (interleukin-3), IL-4 
(interleukin-4), IL-6 (interleukin-6), IL-6sr (interleukin-6 soluble receptor), IL-7 
(interleukin-7), IL-8 (interleukin-8), IL-10 (interleukin-10), IL-11 (interleukin-11), IL-
12p40 (interleukin-12p40), IL-12p70 (interleukin-12p70), IL-13 (interleukin-13), IL-
15 (interleukin-15), IL-16 (interleukin-16), IL-17 (interleukin-17), IP-10 (interferon 
gamma-induced protein 10), MCP-1 (monocyte chemotactic protein-1), MCP-2 
(monocyte chemotactic protein-1), M-CSF (macrophage colony-stimulating 
factor), MIG (monokine induced by gamma interferon), MIP-1α (macrophage 
inflammatory protein-1α), MIP-1β (macrophage inflammatory protein-1β), MIP-1δ 
(macrophage inflammatory protein-1δ), RANTES (regulated and normal T cell 
expressed and secreted), TGF-β1 (transforming growth factor-β1), TNF-α (tumor 
necrosis factor-α), TNF-β (tumor necrosis factor-β), sTNF-R1 (soluble tumor 
necrosis factor-receptor1), sTNF-R2 (soluble tumor necrosis factor-receptor2), 
PDGF-BB (platelet-derived growth factor) and TIMP-2 (tissue inhibitor of 
metalloproteinases-2). 
Although membrane-array and chip-array techniques are both the 
semiquantitative methods of proteomic evaluation, the membrane-array 
technique consists in manual tester evaluation of the chemioluminescent signal  
versus control signal, whereas in the chip-array the genepix instrument directly 
evaluates the fluorescence  signal of the spot versus control signal (which served 
for the normalization calculations). Therefore, in the chip-based array, the optical 
density values are displayed by the instrument. In order to minimize intra- and 
inter-assay variability, only the chip-based array data was used for the final 
statistical evaluation. The single tester handled all the material and followed all 
the phases of the experiment. 
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Figure 27. Protein array on glass-chip: the left one contains 4 chips, the right one 8 
chips. According to the chip-based glass array, 40 inflammatory  proteins were analyzed 
and quantified by GenePix platform. The schematic representation of the array is 
reported below. Each protein is assayed in duplicate. The chip also contains positive and 
negative controls,  IC1, IC2 and IC3  which serve for identification of  the normalization 
factor at the end of the analysis: thereafter, the computer calculates data based on the 
normalization factor.  
 
3.5. Statistical Analysis  
In this study four groups of patients were confronted: controls, diabetics without 
DR, diabetics with diabetic retinopathy (DR), and diabetics with DR and macular 
edema.  
The concentration in the AH of total protein, GFAP, AQP1 and AQP4 was 
quantitatively expressed in reference units (mg/ml, or pg/µg) and, for descriptive 
purposes, the results were reported in terms of mean ± standard deviation. The 
difference in mean protein concentration between the groups was confronted with 
unpaired T-test analysis. The difference in GFAP, AQP1 and AQP4 concentration 
between the groups was confronted using the ANOVA test which, in the case of a 
Array chip
protein array on glass-chip
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statistically significant result (p<0.05), was followed by the Tukey-Kramer post-
hoc analysis. 
A similar analysis was used to evaluate the cytokine concentration, expressed in 
terms of intensity of the fluorescence signal.  
The thickness of retinal layers was expressed in reference units (μm) and 
described in terms of the mean ± standard deviation.  
The mean values of each group were confronted using the repeated measures 
analysis of variances (ANOVA-RM). There were 3 types of analyses conducted:  
- comparison of mean total thickness: each patient has contributed with 
measurements of 60 intervals of the target reference; 
- comparison of the thicknesses of concentric rings (as defined by the 
ETDRS): each patient has contributed with 12 measurements of the 
central ring of 1 mm diameter, 24 measurements of the inner ring of 3 mm 
diameter and 24 measurements of the outer ring of 5 mm diameter;  
- comparison of thicknesses of four sectors (superior (S), nasal (N), inferior 
(I) and temporal (T): each patient has contributed with 15 measurements 
for each sector.  
In cases of significant results (p<0.05), the ANOVA-RM was followed by the 
Bonferroni multiple comparisons post-hoc test.  
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RINGS 
 
SECTORS 
 
Figure 24. Charts of the division of the macular area in rings, sector of the macular area. 
Position in space with respect to the fovea: S, superior; N, nasal; I, inferior; T, temporal, 
CSF, central subfield.  
 
The ANOVA model has also enabled the evaluation of the average profile trend 
of the thicknesses in different patient groups in different retinal areas considered. 
The statistical analysis has been carried out using the SAS® v.9.2 software on a 
personal computer.  
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RESULTS 
4.1. Population 
The data collected refers to 34 eyes of 34 patients hence divided: 12 normal 
subjects (controls), 11 diabetic patients without DR and 11 diabetic patients with 
DR (further divided in 5 patients without DME and 6 with DME). All the patients 
with DR presented non proliferative diabetic retinopathy (NPDR). 
The control group was composed of 5 males and 7 females, between 66 and 87 
years of age (mean age: 75.4±6.4 years), the group of diabetics without DR was 
formed by 3 males and 8 females, between 56 and 86 years of age (mean age 
73.9±9.0 years), while the group of diabetics with DR consisted in 6 males and 5 
females, between 49 and 83 years of age (mean age 69.9±11.4 years), ultimately 
divided in diabetics with DR and without macular edema and diabetics with DR 
and macular edema (tables III and IV). 
Among the diabetic patients without DR, the duration of diabetes mellitus (DM) 
was between 2 and 15 years (mean 7.7±5.1 years), and in all case it was type 2 
DM; among the diabetic patients with DR, the duration was between 10 and 40 
years (mean 20.1±9.8 years); mean duration of DM was 13.4+9.6 years in DR 
without ME and 21.8+11.1 years in DR with ME; and there was 1 case of type 1 
DM, while in the remaining 10 cases it was type 2 DM. In the first group (diabetics 
without DR), 1 patient was in therapy with oral hypoglycemic agents and insulin, 
7 with only the oral hypoglycemic agents, 2 with only the dietary control, while 1 
patient did not assume any preventive action; in the second group (diabetics with 
DR and without ME), 1 patient was in therapy with oral hypoglycemic agents and 
insulin, 1 only with oral hypoglycemic agents, 2 only with insulin, while 1 patient 
limited himself to dietary control; in the third group (diabetics with DR and with 
ME), 1 patient was in therapy with oral hypoglycemic agents and insulin, 1 only 
with oral hypoglycemic agents, 4 only with insulin. 
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In the control group, there were 8 right eyes and 4 left eyes analyzed, with an 
intraocular pressure (IOP) between 12 and 20 mmHg (mean 16.3±2.3 mmHg), 
and a best corrected visual acuity (BCVA) between +1.0 and +0.15 logMar (mean 
0.41±0.22 logMar) in the studied eye; in the group of diabetics without DR, 4 right 
eyes and 7 left eyed were studied, with an IOP comprised between 14 and 22 
mmHg (mean 17.5±2.4 mmHg) and BCVA between +1.0 and +0.1 logMar (mean 
0.58±0.52 logMar) in the studied eye; in the group of diabetics with DR (both 
without and with ME), 6 right eyes and 5 left eyes were studied, with IOP 
comprised between 11 and 18 mmHg (mean 15.7±2.6 mmHg) and BCVA 
between +1.52 and +0.15 (mean 0.63±0.51 logMar) in the studied eye. In the last 
group, 2 patients presented mild NPDR, 8 moderate NPDR and 1 severe NPDR; 
Table IV shows separate data for DR without ME and DR with ME. 
In all 34 cases, the collection of the AH was successful, without contamination by 
blood or by tissues from the anterior chamber of the eye. In average, the quantity 
of the AH collected was superior to 150 μl (150-200 μl). No intra-operative 
complication was registered, and the post-operative management was regular in 
all cases. For every sample, the test tube collection, the freezing, the 
conservation and the dispatch to the laboratory for analysis took place without 
problems.  
 
 
 
Table III. Characteristics of subjects pertaining to four groups. Diabetics w/o RD: 
diabetics without DR; Diabetics w/RD: diabetics with DR; Diabetics w/RD and edema: 
diabetics with DR and macular edema. 
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Table IV. Characteristics of studied eyes in the four groups. Diabetics w/o RD: diabetics 
without DR; Diabetics w/RD: diabetics with DR; Diabetics w/RD and edema: diabetics 
with DR and macular edema. 
PARAMETERS 
Controls 
(N=12) 
Diabetics w/o DR 
(N=11) 
Diabetics w/DR ME- 
(N=5) 
Diabetics w/DR 
ME+ (N=6) 
Studied eye 
(RE:LE) 
8:4 4:7 2:3 4:2 
Mean intraocular 
pression±SD 
(mmHg) 
16.3±2.3 17.5±2.4 15.5±2.7 16.2±2.4 
Visual acuity±SD 
(logMar) 
0.41±0.22 0.58±0.52 0.60±0.38 0.63±0.49 
N° pt with DR     
Mild NPDR - - 1 1 
Moderate NPDR - - 4 4 
Severe NPDR - - 0 1 
PDR - - 0 0 
 
 
 
 
 
 
PARAMETERS 
Controls 
(N=12) 
Diabetics 
w/oDR (N=11) 
Diabetics w/DR 
ME- (N=5) 
Diabetics w/DR 
ME+ (N=6) 
Mean age ± SD 
(yrs) 
75.4 ± 6.4 73.9 ± 9.0 75.8 ± 9.8 62.0 ± 8.6 
Sex (M:F) 5:7 3:8 4:1 2:4 
Mean duration ± SD 
DM (yrs) 
n.a. 7.7 ± 5.1 13.4 ± 9.6 21.8 ± 11.1 
Type DM 
(DM1:DM2) 
n.a. 0:11 0:5 1:5 
DM Treatment     
Oral Hypoglycemics 
+ insulin 
n.a. 1 1 1 
Oral Hypoglycemics n.a. 7 1 1 
Insulin n.a. 0 2 4 
Diet n.a. 2 1 0 
No treatment n.a. 1 0 0 
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4.2. Protein Analysis 
This study evaluated the mean concentrations in the AH of total protein and of 
GFAP, AQP1 and AQP4. The comparison between the four patient groups 
(controls, diabetics without DR, diabetics with DR and no macular edema and 
diabetics with DR and with macular edema) has helped form the following 
observations:  
- Total proteins: no significant difference in mean protein concentration has 
been detected among the controls, diabetics without DR and diabetics 
with DR; 
- Total proteins: a significant difference in  mean protein concentration has 
been detected between the diabetics with DR (and no macular edema) 
and diabetics with macular edema 
 
 
 
Table V. Comparison of the mean concentrations and their standard deviations SD (in 
mg/ml) of total proteins present in the aqueous humour in the four groups. Diabetics w/o 
DR: diabetics without DR; Diabetics w/DR ME-: diabetics with DR and no macular edema; 
Diabetics w/DR ME+: diabetics with DR and macular edema 
 
MEAN CONCENTRATION OF TOTAL PROTEINS ± SD (mg/ml) 
Controls 
(N=12) 
 
Diabetics w/o DR 
(N=11) 
 
Diabetics w/DR ME- 
(N=5) 
 
Diabetics w/DR ME+ (N=6) 
0.44±0.07 0.45±0.10 0.50+0.08 0.37+0.03 
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Figure 25. Mean concentrations of total proteins (in mg/ml) present in the aqueous 
humour of the four groups as detected by Bradford microarray and Nanodrop specific 
evaluation (2uL/595nm; BSA as referring protein). Diab w/o RD: diabetics without DR; 
Diab w/RD: diabetics with DR; Diab w/RD and edema: diabetics with DR and macular 
edema. 
 
- GFAP: the mean concentration is significantly increased in diabetic 
patients with DR compared both to the controls (324.44 pg/µg vs 182.34 
pg/µg; Tukey-Kramer post-hoc test p<0.05) and diabetics without DR 
(324.44 pg/µg vs 165.61 pg/µg; Tukey-Kramer post-hoc test p<0.05); 
- AQP1: the mean concentration is significantly increased in diabetic 
patients with DR compared both to the controls (105.72 pg/µg vs 50.92 
pg/µg; Tukey-Kramer post-hoc test p<0.05) and diabetics without DR 
(105.72 pg/µg vs 28.84 pg/µg; Tukey-Kramer post-hoc test p<0.05); it is 
significantly increased in diabetic subjects with retinopathy and without 
macular edema compared to those with macular edema (105.72pg/µg vs 
37.09pg/µg). 
- AQP4: the mean concentration is significantly increased in diabetic 
patients without DR compared to  controls (206.87pg/µg vs 33,58 pg/µg, 
Tukey-Kramer post-hoc test p<0.05); it is significantly increased in 
Total protein analysis
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Count Mean Variance Std. Dev. Std. Err
A, control
B, Diabetes no RD
C, Diabetes w ith RD
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diabetic patients with DR,  and in diabetic patients with DR and DME 
compared to controls (respectively 852.03 pg/µg vs 33.58 pg/µg, Tukey-
Kramer post-hoc test p<0.05; and 403.08 pg/µg vs 33,58 pg/µg, Tukey-
Kramer post-hoc test p<0.05); it is significantly increased in diabetic 
patients with DR compared to those without DR; (403.08 pg/µg vs 206.87 
pg/µg, Tukey-Kramer post-hoc test p=0.0002); it is significantly increased 
in diabetic patients with DR and no DME compared to diabetic patients 
with DME; (respectively 852.03 pg/µg vs 403.08 pg/µg, Tukey-Kramer 
post-hoc test p=0.02). 
- AQP4/AQP1 concentrations: The Kendall Rank analysis showed weak 
and non significant correlation (Tau=0.21, p=0.3) between these 
biomarkers, despite the trend in increase. 
 
 
Table VI.  Comparison of the mean concentrations and their standard deviations (in 
pg/µg) of proteins GFAP, AQP1 and AQP4 present in aqueous humor of the four groups. 
Diabetics w/o DR: diabetics without DR; Diabetics w/DR ME-: diabetics with DR and no 
macular edema; Diabetics w/DR ME+: diabetics with DR and macular edema. 
 
MEAN CONCENTRATION ± SD (pg/µg) 
Controls 
(N=12) 
Diabetics w/o 
DR 
(N=11) 
 
Diabetics w/DR 
ME- 
(N=5) 
 
Diabetics w/DR  
ME+(N=6) 
GFAP 182.34±114.44 165.61±47.19 324.44±262.54 175.84+76.09 
AQP1 50.92±20.36 28.84±29.96 105.72±15.69 
 
37.09+15.5 
AQP4 33.58±21.20 206.87±491.70 852.03+103.24 403.08±291.61 
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GFAP 
 
 
Figure 26. Mean GFAP concentrations (in pg/µg) in the aqueous humour of the four 
groups. The mean concentration is significantly greater in diabetic patients with DR 
compared both to the controls and diabetics without DR, (p<0.05). Diabetes w/o RD: 
diabetics without DR; Diabetes w/RD: diabetics with DR; Diabetes w/RD and Edema: 
diabetics with DR and macular edema. 
 
 
Figure 27. Percentage (%) variation of GFAP expression in all groups, compared to 
controls. GFAP ELISA assay [millipore.com]: detection range 10 to 0.16 ng/mL (sensitivity less 
than 10pg/mL). Diabetes w/o RD: diabetics without DR; Diabetes w/RD: diabetics with DR; 
Diabetes w/RD and Edema: diabetics with DR and macular edema. 
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Figure 28. Fold changes of GFAP expression in all groups compared to controls. Positive 
fold changes means increase in concentration; negative fold changes means decrease in 
concentration. Diabetes w/o RD: diabetics without DR; Diabetes w/RD: diabetics with DR; 
Diabetes w/RD and Edema: diabetics with DR and macular edema. 
 
 
AQP1 
 
Figure 29. Mean AQP1 concentrations (in pg/µg) in the aqueous humour of the four 
groups. The mean concentration is significantly greater in diabetic patients with DR 
compared both to the controls and diabetics without DR, (p<0.05); it is significantly 
increased in diabetic subjects with retinopathy and without macular edema compared to 
those with macular edema. Diabetes w/o RD: diabetics without DR; Diabetes w/RD: 
diabetics with DR; Diabetes w/RD and Edema: diabetics with DR and macular edema.  
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Figure 30. Fold changes of AQP1 expression in all groups compared to controls. Positive 
fold changes means increase in concentration; negative fold changes means decrease in 
concentration. Diabetes w/o RD: diabetics without DR; Diabetes w/RD: diabetics with DR; 
Diabetes w/RD and Edema: diabetics with DR and macular edema. 
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Figure 31. Mean AQP4 concentrations (in pg/µg) in the aqueous humour of the four 
groups. AQP4 concentration was normalized based on the total protein concentration.  
The mean concentration is significantly increased: in diabetic patients without DR 
compared to  controls, in diabetics with DR,  and in diabetics with DR and DME compared 
to controls; in diabetics with DR compared to those without DR; in diabetics with DR and 
no DME compared to diabetics with DME. Diabetes w/o RD: diabetics without DR; 
Diabetes w/RD: diabetics with DR; Diabetes w/RD and Edema: diabetics with DR and 
macular edema. 
 
 
 
Figure 32. Fold changes of AQP4 expression in all groups compared to controls. Positive 
fold changes means increase in concentration; there are no negative fold changes. 
Diabetes w/o RD: diabetics without DR; Diabetes w/RD: diabetics with DR; Diabetes 
w/RD and Edema: diabetics with DR and macular edema. 
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Figure 33. Mean AQP4 and AQP1 concentrations (in pg/µg) in the aqueous humour of 
the four groups. The Kendall Rank analysis showed weak and non significant correlation 
(Tau=0.21, p=0.3) between these biomarkers, despite the trend in increase. Diabetes w/o 
RD: diabetics without DR; Diabetes w/RD: diabetics with DR; Diabetes w/RD and Edema: 
diabetics with DR and macular edema. 
 
Figure 34. AQP4/AQP1 ratio in all groups. Diabetes w/o RD: diabetics without DR; 
Diabetes w/RD: diabetics with DR; Diabetes w/RD and Edema: diabetics with DR and 
macular edema. 
 
For the different cytokines analyzed, the intensity of the fluorescent signal was 
confronted and the values are represented in table VII. 
 
Table VII. Mean intensity and statistical significance of the fluorescent signal (optical 
density values F532-B532) of the cytokines present in the aqueous humour of the four 
groups in all patients. Significant values are in bold (*p, 0.05, **p, 0.001, ***p,0.0001 
(ANOVA followed by Tukey-Kramer post-hoc). Diabetics w/oDR: diabetics without DR; 
Diabetics w/DR ME-: diabetics with DR and no macular edema; Diabetics w/DR ME+: 
diabetics with DR and with macular edema; monocytochemotactic protein-1 (MCP-1); 
granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-
stimulating factor (GM-CSF),interferon (IFN)-, interferon-inducible 10-kDa protein(IP-10), 
macrophage inflammatory protein-1 alpha (MIP-1a), MIP-1b, platelet-derived growth 
factor (PDGF)-BB, regulated upon activation, normal T cell expressed and secreted, 
tumor necrosis factor alpha (TNF-a), intercellular adhesion molecule-1 (ICAM-1). 
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 1 
Controls 
2 
Diabetics w/o 
DR 
3 
Diabetics w/DR 
ME- 
4 
Diabetics w/DR 
ME+ 
 Mean SD Mean SD Mean SD Mean SD 
Eotaxin 
145.0 299.0 422.0 453.9 925.7 
* 
944.0 544.3 
* 
581.2 
Eotaxin2 248.3 142.8 298.8 557.7 575.2 768.8 972.0 1122 
GCSF 609.2 623.3 381.7 643.0 682.8 682.7 589.5 641.9 
GMCSF 
128.3 287.3 210.8 448.7 685.5 802.2 1213.8 
* 
1485 
ICAM1 109.2 310.4 290.8 382 432.5 503.2 176.5 297.0 
IFNy 
154.8 379.9 495.3 
* 
228.5 434.7 299.0 842.8 
*** 
199.8 
I309 21.5 288.4 30.8 260.4 240.3 381.8 201.0 326.9 
IL1a 310.0 354.8 855.2 867.5 326.5 441.7 508.5 351.6 
IL1b 199.8 452.3 909.0 1049 445.7 714.5 807.2 909.1 
IL2 398.3 405.7 1161.5 1121 954.5 1032 1131.0 1196 
IL3 
880.8 211.8 1307.3 
** 
423.3 955.7 240.5 1050.5 389.1 
IL4 
89.5 158.0 638.7 
* 
710.1 546.5 
* 
540.3 433.2 
* 
515.3 
IL6 894.2 733.2 1063.0 748.0 970.2 677.7 633.0 319.9 
IL6R 323.2 467.5 607.0 500.1 488.3 650.2 458.2 606.5 
IL7 
1805.8 
 
1030 805.8 
* 
755.8 1284.5 1041 797.2 
* 
472.4 
IL8 764.8 661.1 995.2 633.2 859.5 403.9 902.2 328.1 
IL10 135.0 321.0 376.3 353.6 476.7 710.2 666.5 580.3 
IL11 30.8 483.7 95.7 452.9 216.2 519.9 654.2 868.1 
IL12p40 338.0 501.3 186..3 502.8 155.7 604.9 240.8 630.0 
IL12p70 226.2 413.8 68.7 297.9 132.3 408.5 104.5 167.0 
IL13 434.8 506.5 441.5 662.0 418.7 954.2 701.3 697.1 
IL15 863.3 401.7 920.2 585.7 880.8 662.0 1114.0 544.8 
IL16 292.0 370.0 543.5 552.0 522.8 561.9 347.7 402.8 
IL17 
90.0 571.2 1085.7 
* 
1236 383.5 722.1 636.8 901.1 
IP10 
676.5 620.9 1431.5 943.4 1014.8 1228 2260.7 
** 
1087 
MCP1 6464.3 4124 5755.5 3792 6446.0 4682 10799.3 7884 
MCP2 
30.5 396.4 449.8 
* 
299.7 351.0 465.4 64.5 448.0 
MCSF 7059.0 11989 420.7 588.7 274.2 433.6 327.0 343.7 
MIG 474.7 477.0 729.3 701.6 616.3 631.9 664.5 587.2 
MIP1a 
100.5 324.8 179.7 426.9 -19.8 119.0 965.8 
* 
1600 
MIP1b 
644.5 273.2 360.8 444.4 830.3 
** 
240.3 828.0 
** 
75.5 
MIP1d 361.8 514.8 264.0 513.3 645.7 535.9 514.0 694.2 
RANTES 
76.2 159.1 59.2 328.5 657.0 981.8 
 
461.3 652.3 
TGFb1 514.7 613.0 209.2 334.1 255.7 338.6 374.2 395.1 
TNFa 827.5 559.9 1193.5 817.3 1423.2 780.8 1225.5 428.5 
TNFb 
790.8 253.8 1423.7 
*** 
190.2 1579.2 
*** 
339.3 1849.0 
*** 
281.8 
sTNFRI 283.5 259.1 253.7 447.3 557.3 485.9 548.2 674.1 
sTNFRII 160.3 435.4 235.8 245.1 610.2 548.2 843.3 990.6 
PDGF-BB 356.2 387.4 91.8 170.1 225.2 440.9 440.2 414.1 
TIMP2 11440 5074 8585.3 2665 11860.8 5802 13825.2 7013 
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Figure 39.  Bar graph of folds changes of protein expression as inferred from the 
fluorescence detected by antibody microarray techniques in all patients. The instrument 
(genePix) detects the mean values of the column F532-B532 which represents the 
median optical density values of each patient. Statistical analysis was performed on 
single (F532-B532) values. Green: Diabetics with DR and macular edema; Red: Diabetics 
with DR and without macular edema; Blu: Diabetics without DR. Fold changes are 
expressed versus the control group. 
 
The intensity of the signal was significantly greater in diabetic subject without DR 
compared to controls for the following cytokines: IFNy (495.3 vs 154.8, p=0.01), 
IL-3 (1307.3 vs 880.8, p=0.0049), IL-4 (638.7 vs 89.5, p=0.03), IL-17 (1085.7 vs 
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90, p<0.05), TNF-ß (1423.7 vs 790.8, p<0.0001), MCP2 (449.8 vs 30.5, p<0.05), 
The intensity of the IL-7 signal was significantly decreased in diabetic subject 
without DR compared to controls (805.8 vs 1805.8, p=0.01). There was a 
borderline statistical significance in: IL-1a (855.2 vs 310), IL1b (909 vs 199.8), 
MIP1b (360.8 vs 644.5), and MCSF (420.7 vs 7059). 
The intensity of the signal was significantly greater in diabetic subject with DR 
and no macular edema compared to controls for the following cytokines: Eotaxin 
(925.7 vs 145, p=0.03), TNF-ß (1579.2 vs 790.8). There was a borderline 
statistical significance in: IL-4 (546.5 vs 89.5, p=0.04), MCP2 (351 vs 30.5, 
p<0.05), RANTES (657.0 vs 76.2, p=0.04),  sTNFRII (610.2 vs 160.3, p<0.05), 
IFNy (434.7 vs 154.8), TNFα (1423.2 vs 827.5) and MCSF (274.2 vs 7059). 
The intensity of the signal was significantly greater in diabetic subject with DR 
and macular edema compared to controls for the following cytokines: GM-CSF 
(1213.8 vs  128.3, p=0.01), IFNy (842.8 vs 154.8, p<0.0001), IP-10 (2260.7 vs 
676.515.6, p=0.0024),  TNFb (1849 vs 790.8, p<0.0001), MIP1a (965.8 vs 100.5, 
p<0.05), sTNFRII (843.3 vs 160.3, p<0.05). The intensity of the IL-7 signal was 
significantly decreased in diabetic subject with DR and macular edema compared 
to controls (797.2 vs 1805.8, p=0.04). There was a borderline statistical 
significance in: Eotaxin 2 (972 vs 248.3), IL-10 (666.5 vs 135), IL-11 (654.2 vs 
30.8), MCP1 (10799.3 vs 6464.3) and MCSF (327 vs 7059). 
The intensity of the signal was significantly greater in diabetic subject with DR 
and no macular edema compared to diabetic subject without DR for MIP1b 
(830.3 vs 360.8, p<0.05). 
The intensity of the signal was significantly greater in diabetic subject with DR 
and macular edema compared to diabetic subject without DR for the following 
cytokines: TNFb (1849 vs 1423.7, p=0.0031), MIP1b (830.3 vs 444.4, p=0.0096). 
(Table VII) 
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Figure 40. Volcano plots of logarithm of fold-changes versus negative logarithm of 
statistical significance (p values) of cytokines’ expression in aqueous humor of diabetics 
without diabetic retinopathy versus controls; diabetics with diabetic retinopathy and 
without macular edema versus controls, and diabetics with macular edema versus 
controls.  
Diabetics without DR vs Control
Fold-change vs p-value
IFNy
IL-1a IL-1b
IL3
IL4
IL7 IL17
MCP2MCSF
MIP-1b
TNFb
0
1
2
3
4
5
6
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log2(fold-change)
-L
o
g1
0
(p
-v
al
u
e
)
Diabetics with DR and without ME vs Control
Fold-change vs p-value
Eotaxin
IFNg IL-4 MCP2
MCSF
RANTES
TNF-a
TNFb
sTNFRII
0
1
2
3
4
5
6
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log2(fold-change)
-L
o
g1
0
(p
-v
al
u
e
)
Diabetics with DR and with ME vs Control
Fold-change vs p-value
Eotaxin2
GMCSF
IFNy
IL-7
IL-10
IL-11
IP10
MCP-1
M-CSF MIP1a
TNFb
sTNFRII
0
1
2
3
4
5
6
-5 -4 -3 -2 -1 0 1 2 3 4 5
Log2(fold-change)
-L
o
g1
0
(p
-v
al
u
e
)
103 
 
 
Following are some representative chip arrays procedures showing the difference 
in fluorescence signal or fold changes detected by antibody microarray 
techniques in the aqueous humor between controls and different diabetic patients 
groups (diabetics without retinopathy, diabetics with retinopathy and no macular 
edema, and diabetics with retinopathy and macular edema. 
Figure 41. Representative experimental chip-array procedure (Patients: 20, 28, 34, 29). 
All groups were tested in parallel (n=1 patient/group/slide). Green/cy3 signals (specific 
binding) were acquired by GenePix and expressed as F532-B532 median values.  
Positive and negative controls are different and are used by the instrument in order to 
regulate the fluorescent signal. Diabetes: diabetics without retinopathy; Diabetes with RD: 
Diabetics with retinopathy and no Edema, and Diabetes with RD and edema: Diabetics 
with retinopathy and Edema. 
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Figure 42. Bar graph of Single Experiment: According to the chip-based array, 41 
proteins were analysed. Intensity of protein expression as inferred from the fluorescence 
detected by antibody microarray techniques in the aqueous humor of controls, Diabetics 
without retinopathy, Diabetics with retinopathy and no Edema, and Diabetics with 
retinopathy and Edema. Fold changes (increase/decrease) are reported as the ratio 
between the expression intensity of each protein between experimental groups and 
related controls. In the case of results <1, the formula “-1/fold” was applied. Statistical 
analysis was performed according to: ANOVA/two-tailed t-test and Tukey-Kramer post 
hoc. A 1.2 fold cut-off was considered significant. Diabetes: diabetics without retinopathy; 
Diabetes with RD: Diabetics with retinopathy and no Edema, and Diabetes with RD and 
edema: Diabetics with retinopathy and Edema.  
 
 
 
 
Table VIII. Fold changes and statistical significance of the fluorescent signal (optical 
density values F532-B532) of the cytokines present in the aqueous humour of the four 
groups in: patients 28, 34, 29 versus patient 20. Mean of a 1.2 fold cut-off was considered 
significant;. Diabetics w/oDR: diabetics without DR; Diabetics w/DR ME-: diabetics with 
DR and no macular edema; Diabetics w/DR ME+: diabetics with DR and with macular 
edema 
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Chip Folds 
  vs. control vs. Diabetics w/o DR vs. Diabetic w/DR ME- 
Biomarkers 
Diabetic w/o 
DR 
 
 
Diabetic 
w/DR ME-            
 
 
Diabetic 
w/DR ME+  
Diabetic 
w/DR ME-            
 
 
Diabetic 
w/DR ME+         
 
Diabetic w/DR ME+ 
Eotaxin 3,73 7,74 4,91 2,07 1,32 -1,57 
Eotaxin2 2,33 3,26 2,48 1,40 1,06 -1,31 
GCSF 2,01 2,60 2,48 1,30 1,24 -1,05 
GMCSF 1,04 3,99 2,36 3,83 2,26 -1,70 
ICAM1 -1,77 2,39 1,13 4,23 1,99 -2,13 
IFNy 8,40 1,48 11,95 -5,68 1,42 8,08 
I309 -6,13 -1,16 1,81 5,28 11,06 2,10 
IL1a 5,69 -1,38 1,50 -7,86 -3,79 2,07 
IL1b 3,17 1,93 3,07 -1,65 -1,03 1,59 
IL2 3,52 3,49 4,13 -1,01 1,18 1,18 
IL3 1,64 1,06 1,27 -1,55 -1,29 1,20 
IL4 4,47 4,90 2,86 1,10 -1,56 -1,71 
IL6 -1,07 1,05 -1,58 1,12 -1,48 -1,66 
IL6R 1,26 1,46 1,42 1,16 1,13 -1,03 
IL7 -1,17 1,65 -1,09 1,93 1,08 -1,80 
IL8 1,05 -1,25 -1,36 -1,32 -1,43 -1,09 
IL10 1,65 2,79 2,55 1,69 1,55 -1,09 
IL11 -1,76 2,68 4,19 4,72 7,37 1,56 
IL12p40 -3,00 1,07 nd 3,22 nd nd 
IL12p70 0,25 -3,00 -3,61 1,35 1,12 -1,20 
IL13 1,47 nd 2,02 nd 1,38 -16,62 
IL15 1,08 1,23 1,25 1,13 1,15 1,02 
IL16 -1,01 1,82 1,37 1,84 1,38 -1,33 
IL17 3,91 1,75 2,36 -2,24 -1,66 1,35 
IP10 2,49 -1,65 4,72 -4,11 1,89 7,79 
MCP1 1,04 1,27 2,03 1,22 1,94 1,59 
MCP2 1,61 2,63 1,88 1,63 1,17 -1,40 
MCSF 10,95 5,55 7,33 -1,97 -1,49 1,32 
MIG 1,17 1,40 1,48 1,20 1,26 1,05 
MIP1a -1,41 nd 1,15 nd 1,61 -7,55 
MIP1b -48,75 1,40 1,86 68,15 90,45 1,33 
MIP1d -2,49 -3,29 2,57 -1,32 6,39 8,47 
RANTES 1,65 13,58 6,05 8,25 3,68 -2,24 
TGFb1 -2,00 -12,39 -1,20 -6,20 1,66 10,30 
TNFa 1,39 1,60 1,18 1,15 -1,17 -1,35 
TNFb 2,29 2,50 2,53 1,09 1,11 1,01 
sTNFRI 2,08 2,00 3,76 -1,04 1,81 1,88 
sTNFRII 1,15 3,36 6,68 2,92 5,80 1,99 
PDGF-BB -2,82 1,15 1,61 3,24 4,54 1,40 
TIMP2 -1,15 1,03 1,31 1,19 1,51 1,27 
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Figure 43. Representative experimental chip-array procedure (Patients: 16, 18, 32, 26). 
All groups were tested in parallel (n=1 patient/group/slide). Green/cy3 signals (specific 
binding) were acquired by GenePix and expressed as F532-B532 median values. The 
asterisk presents the difference of 4 spots among 4 patients. The artifacts  are due to the 
production or transportation damage. Diabetes: diabetics without retinopathy; Diabetes 
with RD: Diabetics with retinopathy and no Edema, and Diabetes with RD and edema: 
Diabetics with retinopathy and Edema. 
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Figure 44. Bar graph of Single Experiment: Intensity of protein expression as inferred 
from the fluorescence detected by antibody microarray techniques in the 1
st
 detection. 
Fold changes (increase/decrease) are reported as the ratio between the expression 
intensity of each protein between experimental groups and related controls. In the case of 
results <1, the formula “-1/fold” was applied. Statistical analysis was performed according 
to: ANOVA/two-tailed t-test and Tukey-Kramer post-hoc. A 1.2 fold cut-off was considered 
significant. Diabetes: diabetics without retinopathy; Diabetes with RD: Diabetics with 
retinopathy and no Edema, and Diabetes with RD and edema: Diabetics with retinopathy 
and Edema. 
 
 
 
Table IX. Fold changes and statistical significance of the fluorescent signal (optical 
density values F532-B532) of the cytokines present in the aqueous humour of the four 
groups in: patients 18, 32, 26 versus patient 16. Mean of a 1.2 fold cut-off was considered 
significant;. Diabetics w/oDR: diabetics without DR; Diabetics w/DR ME-: diabetics with 
DR and no macular edema; Diabetics w/DR ME+: diabetics with DR and with macular 
edema 
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Chip Folds 
  vs. control vs. Diabetic w/o DR 
vs. Diabetic w/DR 
ME- 
Biomarkers 
Diabetic w/o 
DR 
 
 
Diabetic 
w/DR ME-            
 
 
Diabetic 
w/DR ME+  
Diabetic w/DR 
ME-            
 
 
Diabetic 
w/DR ME+         
 
Diabetic w/DR ME+ 
Eotaxin -1,21 2,23 -1,39 2,69 -1,15 -3,69 
Eotaxin2 -1,30 2,80 8,11 3,63 10,53 -21,36 
GCSF -3,37 -1,70 -2,51 1,98 1,34 1,07 
GMCSF 2,59 3,52 13,42 1,36 5,17 -105,43 
ICAM1 3,70 2,72 1,40 -1,36 -2,64 -6,12 
IFNy 1,25 1,05 1,87 -1,20 1,50 -3,96 
I309 2,32 5,15 2,68 2,22 1,16 -4,39 
IL1a 1,50 1,21 1,32 -1,25 -1,14 -21,36 
IL1b 3,48 1,67 2,23 -2,08 -1,56 -3,84 
IL2 2,24 1,19 1,30 -1,88 -1,71 -3,80 
IL3 1,34 -1,32 -1,46 -1,77 -1,95 -2,29 
IL4 7,40 4,49 5,39 -1,65 -1,37 -4,74 
IL6 1,53 -1,04 -2,51 -1,59 -3,86 -6,28 
IL6R 1,97 1,45 1,22 -1,36 -1,61 -10,01 
IL7 1,22 1,36 -1,25 1,12 -1,53 -5,75 
IL8 1,40 1,19 1,25 -1,18 -1,12 -3,94 
IL10 1,93 2,75 3,51 1,43 1,82 -3,60 
IL11 1,39 1,02 3,45 -1,37 2,48 1,00 
IL12p40 1,28 -4,37 1,87 -5,58 1,46 1,51 
IL12p70 1,37 2,18 -1,02 1,58 -1,40 -6,36 
IL13 -1,24 1,95 -1,01 2,41 1,22 -32,06 
IL15 1,47 -1,03 1,60 -1,51 1,08 -2,76 
IL16 2,25 1,50 -1,17 -1,51 -2,65 -18,59 
IL17 5,23 2,52 4,49 -2,08 -1,16 -5,40 
IP10 3,32 1,61 6,00 -2,06 1,81 -2,32 
MCP1 -1,38 -1,40 1,39 -1,02 1,92 -2,77 
MCP2 3,50 1,76 nd -1,98 nd -1,25 
MCSF 3,07 3,05 2,24 -1,01 -1,37 -5,57 
MIG 2,01 1,11 -1,01 -1,81 -2,02 -4,15 
MIP1a 2,03 -2,69 9,50 -5,46 4,68 1,17 
MIP1b -2,29 1,44 1,70 3,31 3,90 -2,65 
MIP1d 1,02 -1,39 nd -1,42 nd -1,69 
RANTES 1,41 2,64 4,46 1,87 3,17 -11,12 
TGFb1 -2,37 -1,33 -1,94 1,79 1,22 -7,56 
TNFa 1,74 1,66 1,56 -1,05 -1,11 -3,22 
TNFb 2,06 2,00 2,71 -1,03 1,32 -23,34 
sTNFRI -1,95 1,90 -1,10 3,71 1,76 -20,93 
sTNFRII -1,24 1,70 1,16 2,10 1,44 -1,02 
PDGF-BB -3,24 -1,86 -1,34 1,75 2,42 1,98 
TIMP2 -1,26 -1,03 1,00 1,22 1,27 -43,74 
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Figure 45. Bar graph of a Single Experiment: Intensity of protein expression as inferred 
from the fluorescence detected by antibody microarray techniques in the 2
nd
 detection. 
Fold changes (increase/decrease) are reported as the ratio between the expression 
intensity of each protein between experimental groups and related controls. In the case of 
results <1, the formula “-1/fold” was applied to calculate the decrease. Statistical analysis 
was performed according to: ANOVA/two-tailed t-test and Tukey-Kramer post-hoc. A 1.2 
fold cut-off was considered significant. Diabetes: diabetics without retinopathy; Diabetes 
with RD: Diabetics with retinopathy and no Edema, and Diabetes with RD and edema: 
Diabetics with retinopathy and Edema. 
 
 
 
Table X. Fold changes and statistical significance of the fluorescent signal (optical 
density values F532-B532) of the cytokines present in the aqueous humour of the four 
groups in: patients 31, 35, 33 versus patient 24 (control). Mean of a 1.2 fold cut-off was 
considered significant;. Diabetics w/oDR: diabetics without DR (patient 31); Diabetics 
w/DR ME-: diabetics with DR and no macular edema (patient 35); Diabetics w/DR ME+: 
diabetics with DR and with macular edema (patient 33) 
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Chip Folds 
  vs. control vs. Diabetic w/o DR vs. Diabetic w/DR ME-   
Biomarkers 
Diabetic w/o 
DR 
 
 
Diabetic 
w/DR ME-            
 
 
Diabetic 
w/DR ME+  
Diabetic 
w/DR ME-            
 
 
Diabetic w/DR 
ME+         
 
Diabetic w/DR ME+ 
Eotaxin -1,88 -8,77 -8,45 -2,45 -2,11 1,16 
Eotaxin2 3,67 -3,72 -19,75 nd nd -1,88 
GCSF 1,05 -1,83 -1,41 nd nd -36,14 
GMCSF 1,54 -2,09 -3,09 nd nd 18,67 
ICAM1 9,86 
nd 
5,71 nd nd 2,13 
IFNy -6,88 
nd 
-9,83 -5,57 -4,52 1,23 
I309 -5,60 
nd 
-1,60 nd nd 1,50 
IL1a -3,86 
nd 
1,22 -3,22 -8,18 -2,54 
IL1b 1,55 
nd 
-5,73 nd nd 2,93 
IL2 -2,07 -14,61 -1,24 1,12 -4,74 -5,29 
IL3 -9,75 -10,56 -8,16 -408,71 -30,85 13,25 
IL4 -1,15 -12,16 -25,80 nd nd 1,74 
IL6 -1,33 -5,52 -97,50 -6,12 -2,68 2,28 
IL6R -4,97 nd -51,33 nd nd 6,07 
IL7 5,54 nd -12,00 14,95 -3,45 -51,60 
IL8 13,52 -2,03 -1,64 -22,77 -11,91 1,91 
IL10 5,51 -1,67 -3,55 -30,05 4,14 124,50 
IL11 5,22 -5,19 -2,39 nd nd 2,14 
IL12p40 1,97 nd -6,44 nd nd 15,13 
IL12p70 -3,00 -13,97 -6,58 nd nd -2,18 
IL13 -10,67 nd -2,81 nd nd 1,87 
IL15 -4,69 nd -3,57 -1,86 -6,84 -3,68 
IL16 1,38 1,52 -9,75 nd nd 3,46 
IL17 1,23 -8,99 -7,88 nd nd -1,83 
IP10 2,89 -8,98 -63,50 -12,17 -55,47 -4,56 
MCP1 3,63 -27,75 -78,50 -13,79 -6,88 2,00 
MCP2 1,65 nd -17,25 nd nd -9,17 
MCSF -136,75 -32,23 -273,50 nd nd -242,63 
MIG -2,17 -7,86 -150,00 -9,66 1,12 10,80 
MIP1a 4,52 nd -12,20 nd nd 1,35 
MIP1b -1,22 -185,26 -14,56 -266,40 -3,24 82,25 
MIP1d 2,08 -10,88 -5,26 -2,87 -4,29 -1,49 
RANTES 25,65 2,33 1,06 nd nd 3,92 
TGFb1 6,53 nd 5,47 nd nd 2,65 
TNFa -8,25 nd -3,49 -15,11 -103,24 -6,83 
TNFb 116,86 8,28 19,71 -3056,12 -4,84 632,00 
sTNFRI -4,22 1,14 -2,24 nd nd -1,46 
sTNFRII 1,27 nd -68,75 nd nd -31,20 
PDGF-BB 3,01 -2,50 -4,72 33,94 10,68 -3,18 
TIMP2 1,19 nd -2,96 -64,76 -2,37 27,30 
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4.3. Thickness analysis of the retinal layers 
This study has also evaluated the thickness of various retinal layers via the SD-
OCT, considering 60 acquired intervals. The comparison between the 4 different 
groups has been carried out: healthy controls, diabetics without DR, diabetics 
with DR and without DME, and diabetics with DR and DME.  
The mean thickness of various layers (60 intervals per layer) has shown 
significant differences between the 4 groups in the following cases (table VIII):  
- In the patient group with DR and DME, the average thicknesses of RNFL, 
INL and ONL have resulted significantly greater compared to those of the 
other 3 groups (p<0.05); 
- In the patient group with DR and without DME, the RNFL thickness has 
resulted significantly diminished, and the ONL thickness significantly 
increased compared to the controls (p<0.05); in addition, though not 
reaching the level of statistical significance, also in other groups there was 
a tendency to RNFL reduction and ONL increase in diabetic patients 
without DR compared to the controls.   
Table XI. Comparison of the mean thickness and its standard deviation (in μm) of 
different retinal layers in the 4 groups of patients. Diabetics w/o DR: diabetics without 
retinopathy; diabetics w/DR ME-: diabetics with retinopathy and without macular edema; 
diabetics w/DR ME+: diabetics with retinopathy and DME; RNFL: nerve fiber layer; GCL: 
ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer. 
 
LAYER 
MEAN THICKNESS OF RETINAL LAYERS ± SD (μm) 
Controls 
(N=12) 
Diabetics 
w/o DR 
(N=11) 
Diabetics 
w/DR ME- 
(N=5) 
Diabetics 
w/DR ME+ 
(N=6) 
RNFL 26.8±3.4 26.5±2.8 24.3±2.6 37.3±9.9 
GCL 39.4±3.3 40.2±4.6 38.5±2.3 44.1±5.6 
IPL 30.3±1.8 29.7±3.8 29.9±2.9 33.8±2.9 
INL 35.6±4.0 35.1±2.2 36.4±4.3 46.4±1.6 
OPL 23.5±4.5 22.7±3.9 23.9±3.2 30.8±10.1 
ONL 70.3±9.0 72.4±5.6 77.3±7.4 91.8±20.6 
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Figure 46. The mean thickness of different retinal layers (in μm). There is significantly 
higher thicknesses of RNFL, INL and ONL in diabetics with DR and DME compared to 
the other groups (p<0.05); the RNFL thickness is significantly reduced in diabetics with 
DR and without DME compared to controls (p<0.05); significantly greater ONL thickness 
in diabetics with DR and without DME compared to controls (p<0.05). Diabetics w/o DR: 
diabetics without retinopathy; diabetics w/DR ME-: diabetics with retinopathy and without 
macular edema; diabetics w/DR ME+: diabetics with retinopathy and DME; RNFL: nerve 
fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; 
OPL: outer plexiform layer; ONL: outer nuclear layer. 
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have evidenced the significant differences between the 4 groups in the following 
cases (table IX): 
- in RNFL, the thicknesses of the inner and the outer rings are significantly 
greater in diabetics with DR and DME compared to the other groups 
(p<0.05); 
- in INL, the thicknesses of the central and the inner rings are significantly 
greater in diabetics with DR and DME compared to diabetics without DR 
and the controls (p<0.05); 
- in OPL, the thickness of the central ring is significantly greater in diabetics 
with DR and DME compared to the one in the other groups (p<0.05); 
- in ONL, the thicknesses of the central ring and the external one are 
significantly greater in diabetics with DR and DME compared to diabetics 
without DR and the controls (p<0.05). 
It has been moreover detected that the course of the RNFL profile is significantly 
different in diabetics with DR and DME compared to the other groups (p<0.05), 
because of the accentuated increase of the thickness moving from the inside to 
the outside. No significant differences have been found in the course of the 
profiles of the other layers.  
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Table XII. Comparison of the mean thickness and its standard deviation (in μm) per ring 
in different retinal layers of the 4 patient groups. Diabetics nDR: diabetics without 
retinopathy; diabetics DR ME-: diabetics with retinopathy and without macular edema; 
diabetics DR ME+: diabetics with retinopathy and DME; RNFL: nerve fiber layer; GCL: 
ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
plexiform layer; ONL: outer nuclear layer. 
RING 
MEAN THICKNESS PER RING ± SD (μm) 
LAYER 
Controls 
(N=12) 
Diabetics 
w/o DR 
(N=11) 
Diabetics 
w/DR ME- 
(N=5) 
Diabetics 
w/DR ME+ 
(N=6) 
CSF 
RNFL 9.3±3.5 9.0±2.6 8.0±1.8 10.3±2.3 
GCL 13.3±4.5 13.8±5.5 14.6±3.0 16.5±5.1 
IPL 12.4±3.6 12.1±4.3 12.8±5.2 16.2±4.1 
INL 19.3±5.3 18.4±5.1 22.3±3.2 33.2±14.3 
OPL 15.3±5.7 14.6±5.8 13.5±3.7 26.7±11.9 
ONL 97.4±12.9 101.0±9.9 106.9±9.3 129.0±31.1 
INNER 
RNFL 24.3±3.4 25.0±3.8 22.0±2.1 33.4±8.1 
GCL 53.5±6.2 53.5±6.4 50.3±4.1 57.5±9.2 
IPL 36.2±2.6 35.3±5.4 36.8±4.9 41.2±3.4 
INL 43.4±6.0 42.4±4.0 43.7±4.9 56.2±16.9 
OPL 27.3±6.8 26.2±5.1 27.0±4.7 34.0±9.8 
ONL 70.8±10.2 71.5±6.4 78.2±9.1 88.8±23.5 
OUTER 
RNFL 38.1±5.0 36.7±3.0 34.6±4.5 54.7±15.9 
GCL 38.4±4.4 40.2±5.0 38.6±3.3 44.4±4.8 
IPL 33.4±3.6 32.9±3.9 31.5±1.2 35.2±4.8 
INL 36.0±3.9 36.3±2.4 36.1±4.7 43.1±11.0 
OPL 23.8±2.7 23.2±2.7 26.1±3.2 29.7±10.0 
ONL 56.1±8.6 59.1±6.6 61.6±6.5 76.2±22.0 
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Figure 47. Mean thickness per each ring in the different retinal layers (in μm). Diabetics 
w/o DR: diabetics without retinopathy; diabetics w/DR ME-: diabetics with retinopathy and 
without macular edema; diabetics w/DR ME+: diabetics with retinopathy and DME; RNFL: 
nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear 
layer; OPL: outer plexiform layer; ONL: outer nuclear layer. 
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For each layer, the mean thicknesses of the sectors superior, nasal, inferior and 
temporal (15 intervals per sector), have evidenced significant differences 
between the groups in the following cases (table X):  
- in RNFL, the thicknesses of the sectors superior, inferior and temporal 
have resulted significantly greater in diabetics with DR and DME 
compared to the other groups (p<0.05); 
- in GCL, the thickness of the superior sector has resulted significantly 
greater in diabetics with DR and DME compared to diabetics without DR 
and the controls (p<0.05); 
- in INL, the thicknesses of the sectors superior, nasal, inferior and 
temporal have resulted significantly greater in diabetics with DR and DME 
compared to diabetics without DR and the controls (p<0.05); 
- in ONL, the thicknesses of the superior and the inferior sectors have 
resulted significantly greater in diabetics with DR and DME compared to 
diabetics without DR and the controls (p<0.05), while the thickness of the 
temporal sector resulted significantly greater only compared to the 
controls. (p<0.05); 
No significant differences have been detected in the course of the profiles in 
the different sectors.  
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Table XIII. Comparison of the mean thickness and its standard deviation (in μm) per 
sector in different retinal layers of the 4 patient groups. Diabetics w/o DR: diabetics 
without retinopathy; diabetics w/DR ME-: diabetics with retinopathy and without macular 
edema; diabetics w/DR ME+: diabetics with retinopathy and DME; RNFL: nerve fiber 
layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: 
outer plexiform layer; ONL: outer nuclear layer. 
SECTOR 
MEAN THICKNESS PER SECTOR ± SD (μm) 
LAYER 
Controls 
(N=12) 
Diabetics 
w/oDR 
(N=11) 
Diabetics 
w/DR ME- 
(N=5) 
Diabetics 
w/DR ME+ 
(N=6) 
Superior 
RNFL 29.5±4.1 29.2±3.7 26.1±3.6 40.3±11.6 
GCL 39.5±3.5 40.4±3.6 39.9±2.6 45.9±3.8 
IPL 30.1±3.2 29.6±4.7 29.9±1.5 31.4±2.9 
INL 35.5±4.1 36.0±2.7 36.3±4.5 43.1±5.7 
OPL 23.4±3.2 23.8±6.1 28.2±5.8 32.0±10.0 
ONL 70.4±7.7 69.4±6.6 74.4±8.2 85.6±11.2 
Nasal 
RNFL 29.8±5.7 28.6±3.3 27.6±3.3 39.3±17.2 
GCL 41.0±2.9 41.9±6.3 41.5±4.1 46.0±8.3 
IPL 30.1±2.3 29.6±4.2 29.3±4.4 34.6±3.9 
INL 37.2±4.8 35.7±2.4 37.7±3.9 46.8±13.4 
OPL 24.8±9.6 23.8±6.6 23.7±4.9 28.4±4.3 
ONL 71.9±12.5 75.4±6.4 80.8±7.1 84.4±15.0 
Inferior 
RNFL 30.1±3.6 29.1±3.6 27.2±3.2 44.3±12.8 
GCL 38.2±4.5 39.6±4.9 37.3±2.9 42.0±7.6 
IPL 30.2±2.7 29.1±4.0 30.0±2.7 33.2±1.7 
INL 35.4±4.2 34.5±2.1 36.4±3.6 48.7±21.7 
OPL 23.7±4.5 22.6±4.0 24.1±2.8 37.6±27.7 
ONL 66.5±9.1 69.6±6.8 73.7±9.0 98.4±40.3 
Temporal 
RNFL 18.0±2.8 18.9±2.9 16.8±1.5 26.3±1.7 
GCL 39.1±4.7 39.4±5.0 35.6±2.4 42.8±4.0 
IPL 30.8±2.4 30.5±4.8 30.5±6.2 35.8±3.4 
INL 34.4±4.5 34.3±3.3 35.2±6.3 46.7±13.5 
OPL 22.0±4.6 20.6±3.5 20.3±2.6 25.6±1.6 
ONL 72.2±10.7 75.3±8.1 79.9±7.9 98.0±35.0 
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Figure 48. Mean thickness per each sector of the different retinal layers (in μm). Pink 
circles indicate the significant difference between the thickness of the considered layer 
between diabetics with DR and DME compared to other groups (p<0.05); green circles 
indicate the significant difference between diabetics with DR and DME compared to 
diabetics with DR and the controls (p<0.05); blue circles indicate the significant difference 
between diabetics with DR and DME and the controls (p<0.05). Diabetics w/o DR: 
diabetics without retinopathy; diabetics w/DR ME-: diabetics with retinopathy and without 
macular edema; diabetics w/DR ME+: diabetics with retinopathy and DME; RNFL: nerve 
fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; 
OPL: outer plexiform layer; ONL: outer nuclear layer 
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DISCUSSION  
Our study has analyzed for the first time in literature the concentrations in the 
aqueous humour of the proteins of glial origin GFAP, AQP1 and AQP4 in 
subjects afflicted and not afflicted by DM, detecting a significant increase in the 
first group compared to the second one, both in presence of non proliferative DR 
and in its absence. Ours is, moreover, the first study to demonstrate a significant 
increase of different inflammatory cytokines in the AH of diabetic subjects, 
whether they presented a clinically detectable retinal involvement, or not. 
The AH, the vitreous and the lachrymal fluid constantly exchange substances 
with the blood and with ocular tissues: their protein content may therefore be 
considered an extremely useful instrument for the evaluation of the integrity and 
the functionality of the structure of the ocular bulb.[27] Since there have been 
various studies which had demonstrated that the microvascular complications 
caused by DM could alter quantitatively and qualitatively the protein content of 
ocular fluids, it is reasonable to consider possible to identify certain proteins as 
markers which could anticipate the onset of DR. [14, 27, 210-219] It is well known 
that microvascular lesions typical of DR are preceded first by the activation and 
the dysfunction of glial cells and then by the retinal neurodegeneration: for this 
reason, our research was concentrated on the identification of the early 
biomarkers of glial origin found in AH.  
Even though this fluid is not in direct contact with the retina, the proteins released 
by the retina may overflow in it thanks to the diffusion through the vitreous and 
the intraocular structures and to the crossing of the blood-retinal and the blood-
aqueous barriers.[14] In addition, it is known that the collection of the AH is much 
easier and much less invasive than the collection of the vitreous, and that it does 
not imply any additional risk with respect to a normal cataract intervention: for 
these reasons, we believed that this fluid constituted the most adequate choice 
for our research. [220] 
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Despite the ongoing debate on the existence of a connection between the protein 
composition of the AH and the vitreous, the Funatsu and the Ecker groups have 
demonstrated that there is good relationship between the two for many of the 
contained proteins. [215, 217, 220] Our interest has, moreover, been to 
individuate the biomarkers of glial activation which present themselves in different 
concentrations in healthy subjects compared to diabetic subjects with or without 
signs of retinopathy, independently of their vitreous concentration.  
One of the greatest limitations of the use of AH consists in the fact that only small 
volumes, usually around 100-200μl, can be obtained in the collection process. 
These quantities are sufficient only for the evaluation of a limited number of 
proteins via the ELISA test, especially considering that protein concentrations in 
this liquid are extremely low. For this reason, we have decided to use, along with 
the ELISA tests for AQP1, AQP4 and GFAP, also the protein array technique, 
which is able to analyze contemporarily many molecules, which in our case were 
constituted by 40 different cytokines. It is a recently introduced technique in 
continuous evolution, whose validity in recognizing the presence of studied 
molecules was demonstrated by the Sharma group, and confirmed by various 
studies on different cytokines in ocular fluids.[156, 221-223] 
In our study, the mean GFAP concentration results significantly increased in 
diabetic patients with DR compared both to the controls (324.44 pg/µg vs 182.34 
pg/µg) and diabetics without DR (324.44 pg/µg vs 165.61 pg/µg). This protein is 
usually expressed by the glial cells of the CNS, and, in particular, on the retinal 
level in physiological conditions it is expressed only by the astrocytes, while it is 
absent in Müller cells. GFAP, together with other proteins, participates in the 
formation of intermediate filaments of the cellular cytoskeleton, and has an 
important role in the mitotic process, in the maintenance of the blood-encephalic 
and the blood-retinal barriers, as well as in neuronal communication and repair. 
[224-227] During the course of DM, in spite the fact that its expression decreases 
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in astrocytes, this protein is expressed on the retinal level thanks to its increased 
production by the Müller cells. [83, 97-99, 101] The fact that there is a hyper-
expression of GFAP during the course of different neurodegenerative pathologies 
involving not only the retina, but also, more generally, the CNS, explains the 
reason why it is considered a valid marker of glial activation. [149] In particular, 
on the ocular level, the importance of GFAP is evidenced especially after retinal 
insults, since it has been observed that it is very important for the integrity of the 
Müller cells and consequently for the integrity of the internal and the external 
limiting membranes. [149]  
The available studies in literature have analyzed the GFAP expression 
exclusively on the histological level, both in animal and in human tissue; in this 
study, however, we have evaluated the concentration in vivo in AH both in normal 
conditions and in the course of diabetic disease. At the very beginning (in 
diabetics without DR) we found a moderate decrease in GFAP when compared to 
the normal subjects. This may be due to the early atrocyte loss, already 
demonstrated as one of the first signs of neuronal dysfunction in DM. [83] Later 
on, there is a significant increase of GFAP in presence of very initial stages of 
clinically detectable signs of DR, confirming the early activation of the glial 
component in the course of DR (Muller cells).  
Different studies have, in fact, confirmed such hypothesis, suggesting that the 
glial activation could be responsible for the instauration of functional and 
metabolic imbalances of the retina which are the reasons behind both the 
neuronal and the microvascular damage. [89, 90, 93, 94] The increase of GFAP 
in AH would therefore be the consequence both of the normal exchange process 
of the Müller cells, which become hypertrophic and more numerous, and the 
increased apoptotic rate of the astrocytes, and to a lesser degree, of the very 
Müller cells, according to many studies done on animal and human histological 
samples during the course of DM.[93, 94, 150, 228-230]  
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There were no studies in literature which analyzed the aquaporin concentrations 
in ocular fluids, with the exception of two studies by the Ohashi and the Hirai 
groups on AQP5 in lachrymal fluid, respectively during the course of the dry eye 
syndrome and the dacryoadenitis. [231, 232] In order to quantify this protein, 
these studies have made use, as in our case, of the ELISA test, and both studies 
have detected a reduction of AQP5. [231, 232] 
In our study, the AQP4 concentration resulted significantly greater in diabetic 
patients with retinopathy compared both to diabetics without retinopathy and the 
healthy subjects (respectively 852.03pg/µg vs 206.87pg/µg vs 33.58 pg/µg); such 
increase resulted significant also in diabetics without DR compared to healthy 
subjects (206.87pg/µg vs 33.58 pg/µg). AQP4 is a channel protein which permits 
the flow of free water through the cell membrane, and which results present in the 
CNS, in the eye, in the kidney and in the respiratory apparatus. [233] In the eye in 
particular, AQP4 is normally expressed especially by the Müller cells and the 
astrocytes, as well as by the cilliary body epithelium and the lachrymal gland. 
[118, 126, 234] Thanks to its ability to transport free water and its functional 
pairing with potassium channels, AQP4 maintains the osmotic balance between 
the intra- and the extra-cellular matrixes, thus guaranteeing optimal cell 
functioning. [235] The Zhang and the Cui groups have recently evidenced, in the 
experiments on rat retina, that during the course of DM there is an increase in 
AQP4 on the retinal level: it is plausible to suppose that this constitutes a 
compensation attempt with respect to the altered osmotic equilibrium in the retina 
during diabetes.[146, 147] While there are different histological studies done so 
far regarding the variation in AQP4 expression in the retina during the course of 
DM, there are no researches which evaluate its concentration in ocular fluids 
either in healthy subjects or in subjects afflicted with pathologies regarding the 
eye. [97, 121, 146-148] Our study has investigated AQP4 concentrations in 
healthy subjects and in diabetics, noticing a significant increase of this aquaporin 
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in the AH, not only in presence of microvascular alterations typical of DR, but also 
in its subclinical stage. We consider this increase caused, on one part, by the 
natural process of retinal cell metabolism, and, on the other, by the increased cell 
apoptosis which strikes the astrocytes and only marginally the Müller cells: both 
factors would entail the release of this protein in the AH, making it therefore 
detectable at this location. Since AQP4 is expressed especially in the retinal glial 
cells, it is possible to consider this molecule an early and very effective marker of 
retinal damage during the course of DM.  
In our research, we have also detected a significant increase in AQP1 in diabetic 
subjects with retinopathy compared both to diabetics without DR and to healthy 
subjects (respectively 105.72pg/µg vs 28.84pg/µg vs 50.92pg/µg); and in diabetic 
subjects with retinopathy and without macular edema compared to those with 
macular edema (105.72pg/µg vs 37.09pg/µg). This aquaporin, present in the 
CNS, the eye, the kidney and the respiratory apparatus, is usually expressed in 
amacrine cells and the photoreceptors, as well as in the corneal endothelium and 
the iridocorneal trabeculae, in the cilliary body epithelium, in the lens and iris and 
in RPE. [119, 132, 136, 233, 236] Like AQP4, its function is also the regulation of 
the transcellular flow of free water, contributing to the maintenance of osmotic 
balance between the intra- and the extracellular matrixes, hence exercising an 
essential role in the functional maintenance of the cells.[235] There are various 
histological studies both of animal and human tissue, which have analyzed the 
changes in AQP1 expression during the course of DM: they have evidenced its 
presence also in the inner retinal layers, in particular in Müller cells, and the 
substitution of AQP4 with AQP1 in retinal surface vessels, entailing an increase 
in its production. [116, 121, 144, 145] Such hyper-expression would constitute a 
compensation attempt regarding the altered osmotic balance inside the retina 
during the course of DM.[116, 126] Even though many studies were directed at 
the different histological expressions of AQP1 during this pathology, nobody has 
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analyzed the concentrations of this protein in ocular fluids. With the present 
study, however, we have examined the AQP1 concentrations in the AH both in 
the healthy subjects and in the diabetic ones, evidencing the increase of this 
protein in subjects afflicted by DR. In this case, too, the increase is connected to 
the normal process of retinal cell metabolism and to the increased apoptosis 
which affects the astrocytes in particular, and only marginally the Müller cells, 
during the course of DM, with the consequent release of molecules inside ocular 
fluid, especially inside the AH. Since we have not noticed an increase in AQP1 in 
diabetic patients without DR compared to controls, it is possible to consider that 
such increase can be detected exclusively when the retinal damage is clinically 
evident and that it therefore constitutes a modification of glial cells subsequent to 
those previously mentioned.  
AQP1 could therefore constitute a useful marker of glial activation, capable of 
indicating the aggravation of retinal damage during the course of DM.  
A curious finding was the observation of decrease in GFAP, AQP1 and AQP4 in 
diabetics with macular edema compared to diabetics with DR and without ME. 
This might be explained by the anatomic alterations in Muller cells induced by 
cystic spaces caused by edema. The cells are stretched, and reduced in number, 
and therefore this may be the reason for the observed decrease in glial markers 
concentration in ME.  
The data concerning the concentration of different inflammatory cytokines, 
presented in the form of fluorescent signal, has enabled the detection, both in 
diabetic subjects without retinopathy and in those with retinopathy, of a general 
increase in such molecules, in compliance with the hypothesis according to which 
the DR would also be inflammatory in nature. [31] Our study has evidenced how 
the levels of some inflammatory cytokines result higher in diabetic subjects 
without retinopathy compared to normal subjects: IFNy, IL-1a, IL-1b, IL-3, IL-4, 
IL-17, TNF-ß, MCP2; whereas, the IL-7 was significantly decreased in diabetic 
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subjects without DR; an increase has been observed also between the diabetics 
with DR and normal subjects for: Eotaxin, TNF-ß, IL-4, MCP2, RANTES, 
sTNFRII, IFNy, TNF-α ; an increase has been observed also between the 
diabetics with DME and normal subjects for: Eotaxin2, GM-CSF, IFNy, IP-10, 
TNFb, MIP1a, sTNFRII, Il-10, IL-11, MCP1; a significant difference has been 
observed also between the diabetics with DR and those without for: MIP1b, 
TNFb. Therefore, this may be explained by the fact that these cytokines are 
affected by the diabetes-caused retinal damage only in a later stage.  
In our study, therefore, we have noticed especially the significant increase in the 
cytokines produced by the glial cells and in those which attract the circulating 
macrophages to the site of the lesion. This observation confirms the key role that 
these cells hold, not only in presence of microvascular lesions caused by DR, but 
also in the stage before the lesions become clinically detectable. For this reason, 
glial activation would entail the triggering of the inflammatory process responsible 
for the retinal damage, both vascular and nervous.  
In contrast to what has been said for GFAP, AQP1 and AQP4, there are 
numerous studies which have investigated the presence of the inflammatory 
cytokines in AH and the vitreous of diabetic subjects. [155, 219, 222, 237, 238] 
Nevertheless, most of these studies have considered only the subjects who 
presented advanced stages of DR, in many cases already in its proliferative form 
or associated with the macular edema. [215, 217, 219, 222, 223, 237-240] The 
peculiarity of this study consists in the search for the signs of glial activation 
before the onset of microvascular lesions, confirming that both the glial activation 
and the inflammatory response in general can have a crucial role in the formation 
of retinal lesions from the earliest stages of diabetes mellitus. Many studies have 
evidenced an increase in VEGF, a proangiogenic cytokine, and an increase in 
PEDF, with antiangiogenic effect, in diabetic patients afflicted by retinopathy 
compared to non diabetic subjects.[239, 241]  
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We have not, however, analyzed these molecules, since our main interest was to 
concentrate specifically on the glial activation caused by diabetes, and not on the 
retinal angiogenic process.  
With respect to the AH, there are many works which have evidenced an increase 
in inflammatory cytokines in diabetic subjects with retinopathy compared to 
healthy subjects. The cytokines which resulted significantly increased are: MIP-
1β, sICAM-1, IL-6, IL-8, IL-12, IP-10, MCP-1, TGF-β.[155, 156, 215, 219, 222, 
223, 237, 238] Moreover, our study, evidences that IFNy, IL-1a, IL-1b, IL-3, IL-4, 
IL-17, TNF-ß, and MCP2 do not increase only when there are visible signs of 
microvascular lesions, but are increased already at the subclinical stage.  
The works which have analyzed the cytokine concentration in the vitreous or AH 
in presence of proliferative diabetic retinopathy or of macular edema, have 
reported a significant increase in IL-1, IL-3, IL-6, IL-8, IL-10, IL-13, IP-10, MCP-1, 
MIP-1β, PDGF, TNF-α, VEGF, sICAM-1, sVCAM-1, MMP-1, MMP-9, TGF-b, 
PIGF and RANTES compared to non diabetic subjects. [63, 66, 67, 219, 239, 
242, 242-250] In compliance with this data (although we have not included 
patients with PDR and we have evaluated samples of AH which contain a 
significantly lower concentration of cytokines), our study has demonstrated that, 
GM-CSF, IFNy, IP-10, TNFb, MIP1a, sTNFRII, Eotaxin 2, IL-10, IL-11, MCP1 are 
increased in the AH of patients with DME, whereas, IFNy, IL-3, IL-4, IL-17, TNF-
ß, MCP2, IL-1a, IL-1b are increased during the course of DM even  when there 
are no signs of retinopathy. MCP-2 is a monocyte chemotactic factor and 
increased levels of this chemokine suggest an early inflammatory response. [223] 
On the other hand, the late inflammatory response in DR (before the onset of 
new-vessels) was demonstrated by Kyung Oh et al. with higher concentrations of 
MCP1, IP-10, IL-8 in eyes with severe NPDR and PDR, than in eyes with less 
severe DR and normal subjects. [223] This may partially explain differences in 
our results: we have evaluated patients in earlier stages of DR, and therefore 
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these cytokines were increased just in DME patients.  
One of the major limits of this study is the relatively low number of involved 
patients, especially as we divided patients with DR into two groups which were 
separately analyzed. Therefore, statistical significance was not reached (although 
absolute numbers were increased) for several cytokines that have already been 
demonstrated increased in DR. These include: IL-2, IL-13, ICAM1 (see table VII) 
On the other side, a decrease in TGF-b was found, a potent neuroprotective 
factor, even in diabetics without DR.[98] 
We can therefore affirm that, considering the results obtained in our study, there 
are various cytokines which can be considered as early biomarkers of glial 
activation, confirming again the central role of these cells in the pathogenic 
process of DR.  
The obtained results evidence for the first time that all of the glial cell categories 
are activated since the very beginnings of DM, and that their modifications 
constitute a crucial element in the pathogenetic process of DR. The only  
previous work which focused on these cells, conducted by the Nishoikiori group, 
has evidenced in the vitreous of diabetic patients an increase in GDNF (glial cell-
derived neurotrophic factor): this was probably a compensation attempt caused 
by the damage in the blood-retinal barrier during the course of diabetes.[251] 
Nevertheless, our study detects signs of glial activation in the AH already at the 
subclinical stages of DR, when it is still not possible to make any diagnosis based 
on microvascular lesions.  
The identification of retinopathy biomarkers is important for early diagnosis, 
therapy and retinal lesions prognosis during the course of DM. We believe that 
the evidence of the pathogenetic role of glial cells in this microvascular 
complication might lead to new and more efficient therapeutic solutions able to 
improve the outcome of the disease. So far, there is only one study in the 
literature which has investigated the risk markers for the onset of retinopathy 
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during the course of DM; none of the 11 proteins it has individuated is connected 
to glial activation, but only to mechanisms of molecular transport, angiogenesis, 
cellular oxidation, tissue remodeling and cytoprotection. [14] 
The glial activation detected during the course of diabetes mellitus is also 
confirmed by the OCT analysis of the thicknesses of retinal layers.  
In our study, the mean thickness of RNFL in diabetic patients with retinopathy 
and macular edema results significantly increased compared both to controls and 
diabetic subjects without or with retinopathy not associated to macular edema. 
Such increase is statistically significant in the inner and the outer rings and in the 
sectors superior, inferior and temporal of the macular area. We have, moreover, 
observed that in diabetics with retinopathy and macular edema, the behavior of 
RNFL is contrary to the one in the other groups, where there its thickness tends 
to decrease. The increase in RNFL thickness in diabetic subjects with retinopathy 
and edema can be explained, more than as the instauration of the interstitial 
edema (which involves only minimally the nerve fiber layer), with the fact that the 
instrument we used does not allow the distinction of  ILM from RNFL, entailing its 
inclusion in the RNFL measurements. Regarding this matter, histopathologic 
studies have demonstrated that diabetic subjects present an ILM thickening 
caused mainly by the Müller cell alteration, which become hypertrophic and are 
afflicted by proliferation. [252-254] We therefore believe that the RNFL thickening 
we observed is caused prevalently by the increase in number of the Müller cells 
and the swellings of their end-feet on neuronal degeneration, which is thus 
masked by this phenomenon. The tendency of progressive reduction of RNFL 
thickness in the other groups, which reaches statistical significance in diabetic 
patients with retinopathy without macular edema compared to controls, is 
explained by the equally progressive neuronal loss induced by diabetic disease. 
It is well known that the reason behind such phenomenon is the glial cell 
dysfunction, which are no longer able to maintain an adequate osmotic 
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equilibrium between the intra- and the extra-cellular matrixes and which, by 
expressing different proinflammatory cytokines, induce the apoptosis of neuronal 
cells, especially of the ganglion cells, with their consequent axonal degeneration. 
.[73, 83, 98, 99, 108, 109] In compliance with a similar hypothesis, two recent 
studied presented at the ARVO (Association for Research in Vision and 
Ophthalmology) have evidenced certain morphological alterations in vivo of the 
retina of diabetic subjects: the first one has observed a significant increase in 
thickness of ILM, IPL, INL  and a decrease in those of GCL and RNFL in patients 
with non proliferative retinopathy, while the second one noticed the thickening of 
the INL+IPL complex and the presence of microaggregates in ILM and RNFL 
corresponding to the microglia, confirming the early activation of the glial cells in 
the retina during the course of diabetes mellitus. [207, 208] Finally, many works 
have observed the thinning of RNFL and, in some cases, of the GCL+IPL 
complex as well, demonstrating that retinal neurodegeneration constitutes an 
early event in the course of diabetes mellitus, present from the subclinical stages 
of the retinopathy. [201, 204, 255, 256] 
We can therefore affirm that both the protein analysis and the measurement of 
the thicknesses of retinal layers carried out with SD-OCT may provide useful 
information on the activation of the retinal glia during the course of diabetes 
mellitus.  
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CONCLUSIONS 
 
In conclusion, we have demonstrated that, during the course of diabetes mellitus, 
there is a significant increase in the aqueous humour of the protein biomarkers of 
glial activation, not only in presence of advanced stages of diabetic retinopathy, 
but also in its subclinical and early clinical stages. This has confirmed the 
physiopathological role of these cells in the development of this microvascular 
complication, and is a valid reason for considering the proteins derived in this 
way as potential predictors of the development of retinopathy. The proteins for 
which an increase was registered in the aqueous humour of diabetic patients 
(with or without DR) compared to healthy subjects are: GFAP, AQP1, AQP4, 
IFNy, IL-1a, IL-1b, IL-3, IL-4, IL-10, IL-11, IL-17, TNF- α, TNF-ß, MCP1, MCP2, 
Eotaxin, Eotaxin 2, RANTES, sTNFRII, GM-CSF, IP-10, MIP1a, MIP1b; GFAP, 
AQP1 and AQP4 were reduced in diabetic patients with macular edema 
compared to diabetic patients with diabetic retinopathy and no macular edema, 
probably due to anatomic changes of Muller cells. The 23 proteins we have 
individuated may therefore be used in future as possible therapeutic targets for 
the prevention and care of diabetic retinopathy, helping to avoid its onset and 
improving the visual prognosis.  
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